T	B-cell_type
cells	I-cell_type
from	O
renal	O
cell	O
carcinoma	O
patients	O
exhibit	O
an	O
abnormal	O
pattern	O
of	O
kappa	O
B-specific	O
DNA-binding	O
activity	O
:	O
a	O
preliminary	O
report	O
.	O

Recent	O
data	O
suggest	O
that	O
the	O
poor	O
induction	O
of	O
a	O
T-cell	O
response	O
to	O
human	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
may	O
be	O
related	O
to	O
alterations	O
in	O
signal	O
transduction	O
pathways	O
.	O

We	O
report	O
that	O
T	B-cell_type
cells	I-cell_type
from	O
RCC	O
patients	O
have	O
two	O
alterations	O
in	O
kappa	O
B	O
motif-specific	O
DNA-binding	O
activity	O
.	O

The	O
first	O
alteration	O
involves	O
the	O
constitutive	O
expression	O
of	O
substantial	O
kappa	O
B-binding	O
activity	O
in	O
nuclear	O
extracts	O
,	O
which	O
was	O
observed	O
in	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

The	O
magnitude	O
of	O
kappa	O
B	O
activity	O
in	O
unstimulated	B-cell_type
patient	I-cell_type
T	I-cell_type
cells	I-cell_type
was	O
similar	O
to	O
that	O
observed	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
normal	O
individuals	O
that	O
had	O
been	O
activated	O
in	O
vitro	O
.	O

On	O
the	O
basis	O
of	O
Western	O
blotting	O
experiments	O
using	O
antibodies	B-protein
to	O
kappa	B-protein
B/Rel	I-protein
family	I-protein
proteins	I-protein
,	O
the	O
kappa	O
B-binding	O
activity	O
constitutively	O
expressed	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
RCC	O
patients	O
is	O
composed	O
mostly	O
of	O
the	O
NF-kappa	B-protein
B1	I-protein
(	I-protein
p50	I-protein
)	I-protein
subunit	I-protein
.	O

The	O
second	O
abnormality	O
in	O
kappa	O
B-binding	O
activity	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
these	O
patients	O
is	O
that	O
RelA	B-protein
,	O
a	O
member	O
of	O
the	O
Rel	B-protein
homology	I-protein
family	I-protein
which	O
is	O
part	O
of	O
the	O
normal	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
,	O
was	O
not	O
induced	O
in	O
the	O
nucleus	O
following	O
activation	O
.	O

Western	O
blotting	O
analysis	O
did	O
not	O
detect	O
any	O
RelA	B-protein
in	O
nuclear	O
extracts	O
either	O
before	O
or	O
after	O
stimulation	O
of	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
altered	O
kappa	O
B-binding	O
activity	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
RCC	O
patients	O
may	O
impair	O
their	O
capacity	O
to	O
respond	O
normally	O
to	O
various	O
stimuli	O
.	O

[	NULL
CANCER	NULL
RESEARCH	NULL
54	NULL
,	NULL
5424-5429	NULL
,	NULL
October	NULL
15	NULL
,	NULL
1994	NULL
]	NULL
T	NULL
Cells	NULL
from	NULL
Renal	NULL
Cell	NULL
Carcinoma	NULL
Patients	NULL
Exhibit	NULL
an	NULL
Abnormal	NULL
Pattern	NULL
of	NULL
«	NULL
B-specific	NULL
DNA-binding	NULL
Activity	NULL
:	NULL
A	NULL
Preliminary	NULL
Report	NULL
'	NULL
Xiaoli	NULL
Li	NULL
,	NULL
Jun	NULL
Liu	NULL
,	NULL
Jeong-Kyu	NULL
Park	NULL
,	NULL
Thomas	NULL
A.	NULL
Hamilton	NULL
,	NULL
Patricia	NULL
Rayman	NULL
,	NULL
Eric	NULL
Klein	NULL
,	NULL
Mark	NULL
Edinger	NULL
,	NULL
Raymond	NULL
Tubbs	NULL
,	NULL
Ronald	NULL
Bukowski	NULL
,	NULL
and	NULL
James	NULL
Finke	NULL
Departments	NULL
of	NULL
Immunology	NULL
[	NULL
X.	NULL
L.	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
J-K.	NULL
P.	NULL
,	NULL
T.	NULL
A.	NULL
H.	NULL
,	NULL
P.	NULL
R.	NULL
,	NULL
J.	NULL
F.	NULL
}	NULL
,	NULL
Urology	NULL
[	NULL
E.	NULL
K.	NULL
]	NULL
,	NULL
Anatomic	NULL
Pathology	NULL
[	NULL
M.	NULL
E.	NULL
,	NULL
R.	NULL
T.	NULL
]	NULL
,	NULL
and	NULL
Hematology-Oncology	NULL
{	NULL
[	NULL
R	NULL
.	NULL

B	NULL
.	NULL
]	NULL

,	NULL
The	NULL
Cleveland	NULL
Clinic	NULL
Foundation	NULL
,	NULL
Cleveland	NULL
,	NULL
Ohio	NULL
44195	NULL
ABSTRACT	NULL
Recent	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
poor	NULL
induction	NULL
of	NULL
a	NULL
T-cell	NULL
response	NULL
to	NULL
human	NULL
renal	NULL
cell	NULL
carcinoma	NULL
(	NULL
RCC	NULL
)	NULL
may	NULL
be	NULL
related	NULL
to	NULL
alterations	NULL
in	NULL
signal	NULL
transduction	NULL
pathways	NULL
.	NULL

We	NULL
report	NULL
that	NULL
T	NULL
cells	NULL
from	NULL
RCC	NULL
patients	NULL
have	NULL
two	NULL
alterations	NULL
in	NULL
xB	NULL
motif-specific	NULL
DNA-binding	NULL
activity	NULL
.	NULL

The	NULL
first	NULL
alteration	NULL
involves	NULL
the	NULL
constitutive	NULL
expression	NULL
of	NULL
substantial	NULL
«	NULL
B-binding	NULL
activity	NULL
in	NULL
nuclear	NULL
extracts	NULL
,	NULL
which	NULL
was	NULL
observed	NULL
in	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
.	NULL

The	NULL
magnitude	NULL
of	NULL
xB	NULL
activity	NULL
in	NULL
unstimulated	NULL
patient	NULL
T	NULL
cells	NULL
was	NULL
similar	NULL
to	NULL
that	NULL
observed	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
normal	NULL
individuals	NULL
that	NULL
had	NULL
been	NULL
activated	NULL
in	NULL
vitro	NULL
.	NULL

On	NULL
the	NULL
basis	NULL
of	NULL
Western	NULL
blotting	NULL
experiments	NULL
using	NULL
antibodies	NULL
to	NULL
xB/Rel	NULL
family	NULL
proteins	NULL
,	NULL
the	NULL
«	NULL
B-binding	NULL
activity	NULL
constitutively	NULL
expressed	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
RCC	NULL
patients	NULL
is	NULL
composed	NULL
mostly	NULL
of	NULL
the	NULL
NF-B1	NULL
(	NULL
p50	NULL
)	NULL
subunit	NULL
.	NULL

The	NULL
second	NULL
abnormality	NULL
in	NULL
xB-binding	NULL
activity	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
these	NULL
patients	NULL
is	NULL
that	NULL
RelA	NULL
,	NULL
a	NULL
member	NULL
of	NULL
the	NULL
Rel	NULL
homology	NULL
family	NULL
which	NULL
is	NULL
part	NULL
of	NULL
the	NULL
normal	NULL
NF-B	NULL
complex	NULL
,	NULL
was	NULL
not	NULL
induced	NULL
in	NULL
the	NULL
nucleus	NULL
following	NULL
activation	NULL
.	NULL

Western	NULL
blotting	NULL
analysis	NULL
did	NULL
not	NULL
detect	NULL
any	NULL
RelA	NULL
in	NULL
nuclear	NULL
extracts	NULL
either	NULL
before	NULL
or	NULL
after	NULL
stimulation	NULL
of	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
altered	NULL
«	NULL
B-binding	NULL
activity	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
RCC	NULL
patients	NULL
may	NULL
impair	NULL
their	NULL
capacity	NULL
to	NULL
respond	NULL
normally	NULL
to	NULL
various	NULL
stimuli	NULL
.	NULL

INTRODUCTION	NULL
T	NULL
cells	NULL
represent	NULL
an	NULL
important	NULL
component	NULL
of	NULL
the	NULL
host	NULL
immune	NULL
response	NULL
to	NULL
tumors	NULL
.	NULL

The	NULL
activation	NULL
and	NULL
potentiation	NULL
of	NULL
T-cell	NULL
immunity	NULL
is	NULL
a	NULL
goal	NULL
of	NULL
many	NULL
forms	NULL
of	NULL
cancer	NULL
immunotherapy	NULL
including	NULL
cytokine	NULL
and	NULL
adoptive	NULL
cell	NULL
treatment	NULL
(	NULL
1-10	NULL
)	NULL
.	NULL

However	NULL
,	NULL
there	NULL
is	NULL
evidence	NULL
documenting	NULL
that	NULL
T-cell	NULL
immunity	NULL
fails	NULL
to	NULL
develop	NULL
or	NULL
is	NULL
suppressed	NULL
in	NULL
the	NULL
tumor	NULL
bearing	NULL
host	NULL
(	NULL
11-13	NULL
)	NULL
.	NULL

Defects	NULL
in	NULL
delayed	NULL
type	NULL
hypersensitivity	NULL
(	NULL
14	NULL
)	NULL
,	NULL
cytotoxicity	NULL
(	NULL
14	NULL
,	NULL
15	NULL
)	NULL
,	NULL
proliferation	NULL
(	NULL
14	NULL
,	NULL
15-18	NULL
)	NULL
,	NULL
and	NULL
IL-2	NULL
``	NULL
production	NULL
(	NULL
14	NULL
)	NULL
have	NULL
been	NULL
reported	NULL
in	NULL
cancer	NULL
patients	NULL
.	NULL

In	NULL
the	NULL
murine	NULL
colon	NULL
tumor	NULL
model	NULL
MCA-38	NULL
,	NULL
decreased	NULL
T-cell	NULL
cytotoxic	NULL
activity	NULL
is	NULL
seen	NULL
during	NULL
tumor	NULL
progression	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Recent	NULL
work	NULL
in	NULL
this	NULL
model	NULL
has	NULL
documented	NULL
that	NULL
tumor-bearing	NULL
mice	NULL
are	NULL
missing	NULL
TCRZ	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
protein	NULL
tyrosine	NULL
kinases	NULL
p56	NULL
``	NULL
and	NULL
p59	NULL
``	NULL
(	NULL
20	NULL
)	NULL
.	NULL

We	NULL
have	NULL
found	NULL
similar	NULL
alterations	NULL
in	NULL
these	NULL
signaling	NULL
elements	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
RCC	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Although	NULL
changes	NULL
in	NULL
these	NULL
molecules	NULL
were	NULL
observed	NULL
with	NULL
T	NULL
cells	NULL
from	NULL
both	NULL
the	NULL
blood	NULL
and	NULL
tumor	NULL
,	NULL
tumor-derived	NULL
lymphocytes	NULL
were	NULL
more	NULL
severely	NULL
affected	NULL
.	NULL

Depressed	NULL
levels	NULL
of	NULL
TCRZ	NULL
were	NULL
also	NULL
observed	NULL
in	NULL
tumor-derived	NULL
T	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
colorectal	NULL
carcinoma	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Given	NULL
the	NULL
importance	NULL
of	NULL
TCR	NULL
,	NULL
p56	NULL
``	NULL
,	NULL
and	NULL
pS59®	NULL
``	NULL
in	NULL
T-cell	NULL
activation	NULL
(	NULL
23	NULL
)	NULL
,	NULL
defects	NULL
in	NULL
their	NULL
expression	NULL
may	NULL
cause	NULL
alteration	NULL
in	NULL
downstream	NULL
signaling	NULL
events	NULL
including	NULL
the	NULL
activation	NULL
and/or	NULL
nuclear	NULL
translocation	NULL
of	NULL
transcription	NULL
factors	NULL
(	NULL
24	NULL
)	NULL
.	NULL

In	NULL
this	NULL
report	NULL
we	NULL
determined	NULL
if	NULL
alterations	NULL
in	NULL
signaling	NULL
elements	NULL
of	NULL
Received	NULL
5/11/94	NULL
;	NULL
accepted	NULL
8/17/94	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
advertisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL
'	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
USPHS	NULL
Grant	NULL
CA	NULL
56937	NULL
.	NULL

*	NULL
To	NULL
whom	NULL
requests	NULL
for	NULL
reprints	NULL
should	NULL
be	NULL
addressed	NULL
,	NULL
at	NULL
The	NULL
Cleveland	NULL
Clinic	NULL
Foundation	NULL
,	NULL
9500	NULL
Euclid	NULL
Avenue	NULL
,	NULL
Cleveland	NULL
,	NULL
OH	NULL
44195	NULL
.	NULL

*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
IL-2	NULL
,	NULL
interleukin	NULL
2	NULL
;	NULL
RCC	NULL
,	NULL
renal	NULL
cell	NULL
carcinoma	NULL
;	NULL
T	NULL
cell	NULL
receptor	NULL
{	NULL
;	NULL
PBL	NULL
,	NULL
peripheral	NULL
blood	NULL
lymphocyte	NULL
;	NULL
TIL	NULL
,	NULL
tumor-infiltrating	NULL
lymphocyte	NULL
;	NULL
HEPES	NULL
,	NULL
4-	NULL
(	NULL
2-hydroxyethy1	NULL
)	NULL
-1-piperazineethanesulfonic	NULL
acid	NULL
;	NULL
DTT	NULL
,	NULL
dithiothreitol	NULL
;	NULL
PMSF	NULL
,	NULL
phenylmethylsulfony	NULL
]	NULL
fluoride	NULL
;	NULL
PKC	NULL
,	NULL
protein	NULL
kinase	NULL
C	NULL
;	NULL
IFN-y	NULL
,	NULL
y	NULL
interferon	NULL
;	NULL
IL-2Ra	NULL
,	NULL
interleukin	NULL
2	NULL
receptor	NULL
a.	NULL
T	NULL
cells	NULL
from	NULL
RCC	NULL
patients	NULL
include	NULL
abnormalities	NULL
in	NULL
«	NULL
B	NULL
sequence	NULL
motif-specific	NULL
binding	NULL
activity	NULL
(	NULL
25	NULL
)	NULL
.	NULL

The	NULL
regulation	NULL
of	NULL
many	NULL
cellular	NULL
gene	NULL
products	NULL
associated	NULL
with	NULL
T-lymphocyte	NULL
activation	NULL
including	NULL
cytokines	NULL
and	NULL
the	NULL
IL-2Ra	NULL
chain	NULL
involves	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

The	NULL
«	NULL
B	NULL
enhancer-binding	NULL
proteins	NULL
are	NULL
composed	NULL
of	NULL
a	NULL
family	NULL
of	NULL
related	NULL
proteins	NULL
that	NULL
include	NULL
NF-	NULL
«	NULL
B1	NULL
(	NULL
p50	NULL
)	NULL
,	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
,	NULL
and	NULL
c-Rel	NULL
(	NULL
26-33	NULL
)	NULL
.	NULL

These	NULL
proteins	NULL
and	NULL
other	NULL
members	NULL
of	NULL
the	NULL
«	NULL
B/Rel	NULL
family	NULL
share	NULL
amino	NULL
acid	NULL
sequence	NULL
homology	NULL
within	NULL
a	NULL
region	NULL
that	NULL
is	NULL
responsible	NULL
for	NULL
DNA	NULL
binding	NULL
and	NULL
dimerization	NULL
(	NULL
34	NULL
)	NULL
.	NULL

In	NULL
T	NULL
cells	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
inducible	NULL
and	NULL
is	NULL
regulated	NULL
at	NULL
a	NULL
posttranslational	NULL
level	NULL
(	NULL
26	NULL
,	NULL
28	NULL
,	NULL
34	NULL
)	NULL
.	NULL

Stimulation	NULL
of	NULL
T	NULL
cells	NULL
with	NULL
mito-gens	NULL
,	NULL
phorbol	NULL
esters	NULL
,	NULL
anti-CD3	NULL
antibody	NULL
,	NULL
and	NULL
certain	NULL
cytokines	NULL
such	NULL
as	NULL
IL-2	NULL
induces	NULL
the	NULL
release	NULL
of	NULL
the	NULL
preformed	NULL
cytoplasmic	NULL
NF-	NULL
«	NULL
B	NULL
complex	NULL
from	NULL
an	NULL
inactive	NULL
complex	NULL
with	NULL
an	NULL
inhibitor	NULL
,	NULL
allowing	NULL
the	NULL
active	NULL
form	NULL
to	NULL
translocate	NULL
to	NULL
the	NULL
nucleus	NULL
(	NULL
26	NULL
,	NULL
34	NULL
,	NULL
35	NULL
)	NULL
.	NULL

The	NULL
work	NULL
presented	NULL
here	NULL
indicates	NULL
that	NULL
T	NULL
cells	NULL
from	NULL
RCC	NULL
patients	NULL
have	NULL
an	NULL
abnormality	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
nuclear	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

This	NULL
includes	NULL
the	NULL
constitutive	NULL
expression	NULL
of	NULL
NF-	NULL
«	NULL
B1	NULL
and	NULL
the	NULL
failure	NULL
to	NULL
activate	NULL
other	NULL
members	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
family	NULL
which	NULL
are	NULL
part	NULL
of	NULL
the	NULL
normal	NULL
complex	NULL
found	NULL
in	NULL
the	NULL
nucleus	NULL
after	NULL
stimulation	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Isolation	NULL
of	NULL
T	NULL
Cells	NULL
from	NULL
Peripheral	NULL
Blood	NULL
and	NULL
Tumor	NULL
.	NULL

TIL	NULL
cells	NULL
were	NULL
isolated	NULL
from	NULL
surgical	NULL
specimens	NULL
from	NULL
patients	NULL
with	NULL
renal	NULL
cell	NULL
carcinoma	NULL
(	NULL
n	NULL
=	NULL
13	NULL
)	NULL
participating	NULL
in	NULL
protocols	NULL
at	NULL
the	NULL
Cleveland	NULL
Clinic	NULL
.	NULL

All	NULL
TIL	NULL
preparations	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
primary	NULL
tumor	NULL
.	NULL

PBLs	NULL
were	NULL
obtained	NULL
from	NULL
12	NULL
patients	NULL
3-5	NULL
days	NULL
after	NULL
their	NULL
surgery	NULL
.	NULL

Seven	NULL
of	NULL
the	NULL
PBLs	NULL
had	NULL
paired	NULL
TIL	NULL
samples	NULL
.	NULL

TILs	NULL
were	NULL
obtained	NULL
from	NULL
tumor	NULL
after	NULL
a	NULL
2-h	NULL
digestion	NULL
at	NULL
37°C	NULL
using	NULL
collagenase	NULL
type	NULL
II	NULL
(	NULL
3.5	NULL
mg/m	NULL
}	NULL
;	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
and	NULL
egg	NULL
white	NULL
trypsin	NULL
inhibitor	NULL
(	NULL
1	NULL
mg/ml	NULL
;	NULL
Sigma	NULL
)	NULL
(	NULL
18	NULL
,	NULL
21	NULL
)	NULL
.	NULL

TILs	NULL
were	NULL
centrifuged	NULL
over	NULL
Ficoll-Hypaque	NULL
,	NULL
and	NULL
T	NULL
lymphocytes	NULL
were	NULL
enriched	NULL
by	NULL
passing	NULL
cells	NULL
over	NULL
a	NULL
nylon	NULL
wool	NULL
column	NULL
followed	NULL
by	NULL
negative	NULL
selection	NULL
(	NULL
magnetic	NULL
cell	NULL
separation	NULL
;	NULL
Miltenyi	NULL
Biotec	NULL
Inc.	NULL
,	NULL
Sunnyvale	NULL
,	NULL
CA	NULL
)	NULL
using	NULL
the	NULL
following	NULL
microbead-conjugated	NULL
monoclonal	NULL
antibodies	NULL
:	NULL
anti-CD16	NULL
(	NULL
natural	NULL
killer	NULL
cells	NULL
)	NULL
;	NULL
anti-CD19	NULL
(	NULL
B	NULL
cells	NULL
)	NULL
;	NULL
and	NULL
anti-CD14	NULL
(	NULL
macrophages	NULL
)	NULL
(	NULL
21	NULL
)	NULL
.	NULL

PBL-derived	NULL
T	NULL
cells	NULL
(	NULL
RCC	NULL
patients	NULL
,	NULL
n	NULL
=	NULL
12	NULL
;	NULL
normals	NULL
,	NULL
n	NULL
=	NULL
7	NULL
)	NULL
were	NULL
obtained	NULL
following	NULL
Ficoll-Hypaque	NULL
density	NULL
separation	NULL
and	NULL
negative	NULL
selection	NULL
using	NULL
the	NULL
same	NULL
antibody	NULL
mixture	NULL
described	NULL
for	NULL
TIL	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Immunostaining	NULL
with	NULL
anti-CD3	NULL
antibody	NULL
after	NULL
enrichment	NULL
demonstrated	NULL
that	NULL
the	NULL
T-cell	NULL
purity	NULL
was	NULL
greater	NULL
than	NULL
90	NULL
%	NULL
.	NULL

Oligonucleotides	NULL
Used	NULL
in	NULL
Assays	NULL
.	NULL

The	NULL
synthetic	NULL
oligonucleotide	NULL
containing	NULL
a	NULL
tandem	NULL
repeat	NULL
of	NULL
the	NULL
consensus	NULL
sequence	NULL
for	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
DNA-binding	NULL
site	NULL
was	NULL
obtained	NULL
from	NULL
GIBCO-BRL	NULL
(	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
the	NULL
oligonucleotide	NULL
was	NULL
5'-GATCCAAGGGGACTTTCCATGGATCCAA-GGGGACTITCCATG-3	NULL
'	NULL
.	NULL

The	NULL
oligonucleotide	NULL
corresponding	NULL
to	NULL
the	NULL
«	NULL
B	NULL
element	NULL
from	NULL
IL-2Ra	NULL
gene	NULL
was	NULL
prepared	NULL
by	NULL
using	NULL
an	NULL
Applied	NULL
Biosystems	NULL
oligonucleotide	NULL
synthesizer	NULL
(	NULL
Model	NULL
381	NULL
A	NULL
)	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
the	NULL
oligonucleotide	NULL
was	NULL
5'CAACGGCAGGGGAATCTCCCTCTCCTT-3	NULL
'	NULL
(	NULL
28	NULL
,	NULL
35	NULL
)	NULL
.	NULL

Underlined	NULL
sequences	NULL
represent	NULL
the	NULL
«	NULL
B	NULL
motif	NULL
.	NULL

In	NULL
the	NULL
competition	NULL
studies	NULL
an	NULL
oligonucleotide	NULL
corresponding	NULL
to	NULL
the	NULL
Oct	NULL
enhancer	NULL
element	NULL
was	NULL
used	NULL
(	NULL
GIBCO-BRL	NULL
)	NULL
,	NULL
and	NULL
the	NULL
sequence	NULL
is	NULL
5'GATCATGCAAATGATCATGCAAATGATCATGGA-AAT-3	NULL
'	NULL
.	NULL

For	NULL
the	NULL
preparation	NULL
of	NULL
probes	NULL
in	NULL
electrophoresis	NULL
mobility	NULL
shift	NULL
assay	NULL
,	NULL
radiolabeled	NULL
double-stranded	NULL
oligonucleotides	NULL
were	NULL
prepared	NULL
by	NULL
annealing	NULL
coding	NULL
strand	NULL
template	NULL
to	NULL
a	NULL
complementary	NULL
10-base	NULL
primer	NULL
and	NULL
filling	NULL
in	NULL
the	NULL
overhang	NULL
with	NULL
the	NULL
Klenow	NULL
fragment	NULL
of	NULL
DNA	NULL
polymerase	NULL
I	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
[	NULL
«	NULL
-P	NULL
]	NULL
dCTP	NULL
.	NULL

Preparation	NULL
of	NULL
Nuclear	NULL
Extract	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
by	NULL
a	NULL
modified	NULL
method	NULL
of	NULL
Osborn	NULL
et	NULL
al	NULL
.	NULL

(	NULL
36	NULL
)	NULL
.	NULL

Isolated	NULL
T	NULL
cells	NULL
(	NULL
10	NULL
'	NULL
)	NULL
were	NULL
washed	NULL
5424	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1994	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

ALTERED	NULL
«	NULL
B	NULL
BINDING	NULL
ACTIVITY	NULL
IN	NULL
T	NULL
CELLS	NULL
twice	NULL
with	NULL
cold	NULL
Hanks	NULL
'	NULL
balanced	NULL
salt	NULL
solution	NULL
and	NULL
the	NULL
cell	NULL
pellet	NULL
was	NULL
suspended	NULL
in	NULL
40	NULL
pl	NULL
of	NULL
hypotonic	NULL
buffer	NULL
A	NULL
[	NULL
10	NULL
mm	NULL
HEPES	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
-10	NULL
mm	NULL
KCl-1.5	NULL
mm	NULL
MgC1	NULL
;	NULL
-0.1	NULL
mm	NULL
EDTA-1	NULL
mm	NULL
DTT-0.5	NULL
mm	NULL
PMSF-0.1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
}	NULL
for	NULL
10	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

Nuclei	NULL
were	NULL
prepared	NULL
by	NULL
microcentrifugation	NULL
for	NULL
10	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
nuclear	NULL
pellet	NULL
was	NULL
suspended	NULL
in	NULL
15	NULL
ul	NULL
of	NULL
buffer	NULL
C	NULL
[	NULL
20	NULL
mm	NULL
HEPES	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
-25	NULL
%	NULL
glycerol-0.4	NULL
m	NULL
NaCl-1.5	NULL
mm	NULL
MgCl	NULL
,	NULL
-1	NULL
mm	NULL
EDTA-1	NULL
mm	NULL
DTT-0.5	NULL
mm	NULL
PMSF	NULL
]	NULL
and	NULL
incubated	NULL
for	NULL
15	NULL
min	NULL
at	NULL
4°C	NULL
with	NULL
brief	NULL
mixing	NULL
.	NULL

The	NULL
mixture	NULL
was	NULL
microcentrifuged	NULL
(	NULL
16,000	NULL
x	NULL
g	NULL
)	NULL
for	NULL
10	NULL
min	NULL
at	NULL
4°C	NULL
and	NULL
the	NULL
supernatant	NULL
was	NULL
diluted	NULL
with	NULL
60	NULL
pl	NULL
of	NULL
modified	NULL
buffer	NULL
D	NULL
[	NULL
20	NULL
mm	NULL
HEPES	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
-50	NULL
mm	NULL
KCI-0.2	NULL
mm	NULL
EDTA-1	NULL
mm	NULL
DTT-1	NULL
mm	NULL
PMSF	NULL
]	NULL
.	NULL

Protein	NULL
concentration	NULL
was	NULL
measured	NULL
by	NULL
using	NULL
the	NULL
Bradford	NULL
assay	NULL
(	NULL
Bio-Rad	NULL
,	NULL
Richmond	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Electrophoretic	NULL
Mobility	NULL
Shift	NULL
Assay	NULL
.	NULL

As	NULL
previously	NULL
described	NULL
(	NULL
37	NULL
)	NULL
,	NULL
nuclear	NULL
extracts	NULL
(	NULL
5	NULL
ug	NULL
of	NULL
protein	NULL
)	NULL
were	NULL
preincubated	NULL
in	NULL
a	NULL
25-pl	NULL
total	NULL
reaction	NULL
volume	NULL
containing	NULL
20	NULL
mm	NULL
HEPES	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
80	NULL
mm	NULL
NaCl	NULL
,	NULL
0.1	NULL
mm	NULL
EDTA	NULL
,	NULL
1	NULL
mM	NULL
DTT	NULL
,	NULL
8	NULL
%	NULL
glycerol	NULL
,	NULL
and	NULL
2	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
didC	NULL
)	NULL
(	NULL
Pharmacia	NULL
,	NULL
Piscataway	NULL
,	NULL
NJ	NULL
)	NULL
for	NULL
15	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
reaction	NULL
mixture	NULL
was	NULL
then	NULL
incubated	NULL
with	NULL
the	NULL
radiolabeled	NULL
oligonucleotide	NULL
(	NULL
2	NULL
X	NULL
10°	NULL
cpm	NULL
)	NULL
for	NULL
20	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
analyzed	NULL
by	NULL
electrophoresis	NULL
in	NULL
a	NULL
6	NULL
%	NULL
nondenaturing	NULL
polyacryl-amide	NULL
gel	NULL
with	NULL
0.25	NULL
X	NULL
TBE	NULL
buffer	NULL
(	NULL
22.3	NULL
mM	NULL
Tris-22.2	NULL
mm	NULL
boric	NULL
acid-0.5	NULL
mm	NULL
EDTA	NULL
)	NULL
.	NULL

The	NULL
gels	NULL
were	NULL
dried	NULL
and	NULL
analyzed	NULL
by	NULL
autoradiography	NULL
.	NULL

Western	NULL
Blotting	NULL
.	NULL

The	NULL
antibodies	NULL
used	NULL
in	NULL
these	NULL
experiments	NULL
were	NULL
poly-clonal	NULL
rabbit	NULL
anti-mouse	NULL
antibodies	NULL
to	NULL
NF-	NULL
«	NULL
B1	NULL
(	NULL
p50	NULL
)	NULL
and	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
(	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
Ghosh	NULL
,	NULL
National	NULL
Cancer	NULL
Institute	NULL
,	NULL
Frederick	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

Normal	NULL
rabbit	NULL
serum	NULL
(	NULL
2	NULL
pg/pul	NULL
)	NULL
(	NULL
The	NULL
Jackson	NULL
Laboratory	NULL
,	NULL
West	NULL
Grove	NULL
,	NULL
PA	NULL
)	NULL
was	NULL
used	NULL
as	NULL
a	NULL
control	NULL
.	NULL

T	NULL
cells	NULL
were	NULL
lysed	NULL
by	NULL
incubation	NULL
in	NULL
lysis	NULL
buffer	NULL
for	NULL
10	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

Equal	NULL
amounts	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
of	NULL
nuclear	NULL
protein	NULL
from	NULL
cell	NULL
lysates	NULL
were	NULL
electrophoresed	NULL
on	NULL
10	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
gels	NULL
and	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
membranes	NULL
.	NULL

The	NULL
membranes	NULL
were	NULL
washed	NULL
with	NULL
Tris-buffered	NULL
saline-Tween	NULL
(	NULL
0.1	NULL
%	NULL
)	NULL
with	NULL
5	NULL
%	NULL
nonfat	NULL
dried	NULL
milk	NULL
overnight	NULL
at	NULL
4°C	NULL
or	NULL
2	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
and	NULL
then	NULL
blotted	NULL
for	NULL
1-2	NULL
h	NULL
with	NULL
the	NULL
appropriate	NULL
antibody	NULL
.	NULL

The	NULL
membranes	NULL
were	NULL
washed	NULL
with	NULL
Tris-buffered	NULL
saline-Tween	NULL
and	NULL
incubated	NULL
with	NULL
a	NULL
1:1000	NULL
dilution	NULL
of	NULL
horseradish	NULL
peroxidase-conjugated	NULL
anti-rabbit	NULL
or	NULL
anti-mouse	NULL
immunoglobulin	NULL
(	NULL
Amersham	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
.	NULL

Thereafter	NULL
,	NULL
membranes	NULL
were	NULL
developed	NULL
with	NULL
enhanced	NULL
chemiluminescence	NULL
reagents	NULL
(	NULL
DuPont	NULL
New	NULL
England	NULL
Nuclear	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
)	NULL
and	NULL
exposed	NULL
to	NULL
film	NULL
.	NULL

RESULTS	NULL
T-cell	NULL
Nuclear	NULL
Extracts	NULL
from	NULL
RCC	NULL
Patients	NULL
Display	NULL
Altered	NULL
«	NULL
B-specific	NULL
Binding	NULL
Activity	NULL
.	NULL

We	NULL
determined	NULL
whether	NULL
the	NULL
defects	NULL
in	NULL
T-cell-signaling	NULL
elements	NULL
from	NULL
RCC	NULL
patients	NULL
involved	NULL
abnormal	NULL
«	NULL
B-specific	NULL
DNA-binding	NULL
activity	NULL
.	NULL

To	NULL
address	NULL
this	NULL
question	NULL
,	NULL
T	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
medium	NULL
alone	NULL
or	NULL
with	NULL
one	NULL
of	NULL
the	NULL
following	NULL
stimuli	NULL
;	NULL
IL-2	NULL
;	NULL
cross-linked	NULL
anti-CD3	NULL
antibody	NULL
;	NULL
or	NULL
both	NULL
.	NULL

After	NULL
4	NULL
h	NULL
of	NULL
incubation	NULL
nuclear	NULL
extract	NULL
was	NULL
isolated	NULL
since	NULL
kinetic	NULL
studies	NULL
from	NULL
our	NULL
laboratory	NULL
and	NULL
others	NULL
(	NULL
35	NULL
)	NULL
have	NULL
shown	NULL
that	NULL
maximinal	NULL
levels	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
are	NULL
detectable	NULL
in	NULL
the	NULL
nucleus	NULL
at	NULL
this	NULL
time	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
tumor	NULL
and	NULL
peripheral	NULL
blood	NULL
derived	NULL
T	NULL
cells	NULL
were	NULL
reacted	NULL
with	NULL
a	NULL
{	NULL
°°P	NULL
]	NULL
dATP-radiolabeled	NULL
oligonucleotide	NULL
containing	NULL
tandem	NULL
repeats	NULL
of	NULL
the	NULL
«	NULL
B	NULL
recognition	NULL
sequence	NULL
.	NULL

The	NULL
DNA-protein	NULL
complexes	NULL
were	NULL
separated	NULL
from	NULL
free	NULL
oligonucleotide	NULL
by	NULL
nondenaturing	NULL
acrylamide	NULL
gel	NULL
electro-phoresis	NULL
.	NULL

The	NULL
nucleoprotein	NULL
complex	NULL
obtained	NULL
with	NULL
T	NULL
cells	NULL
from	NULL
RCC	NULL
patients	NULL
was	NULL
compared	NULL
to	NULL
that	NULL
from	NULL
T	NULL
cells	NULL
of	NULL
healthy	NULL
volunteers	NULL
.	NULL

A-	NULL
B-Patient	NULL
Normal	NULL
Patient	NULL
Normal	NULL
TL	NULL
PBL	NULL
PBL	NULL
Til	NULL
PBL	NULL
PBL	NULL
|	NULL
1	NULL
T	NULL
1	NULL
T	NULL
1	NULL
me	NULL
J	NULL
1	NULL
d	NULL
M	NULL
U	NULL
IL2	NULL
-	NULL
a	NULL
00	NULL
%	NULL
-	NULL
+	NULL
a	NULL
+	NULL
+00	NULL
+	NULL
>	NULL
o	NULL
+	NULL
+	NULL
+	NULL
+	NULL
;	NULL
Competitor	NULL
.	NULL

-	NULL
-	NULL
+	NULL
-	NULL
-	NULL
+	NULL
+0	NULL
+	NULL
Competitor	NULL
-	NULL
meud	NULL
*	NULL
*	NULL
*	NULL
IL2Ra	NULL
«	NULL
B	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

T	NULL
cells	NULL
from	NULL
RCC	NULL
patients	NULL
have	NULL
altered	NULL
«	NULL
B-binding	NULL
activity	NULL
.	NULL

T	NULL
cells	NULL
from	NULL
RCC	NULL
patients	NULL
(	NULL
blood	NULL
and	NULL
tumor	NULL
)	NULL
and	NULL
from	NULL
normal	NULL
individuals	NULL
were	NULL
cultured	NULL
with	NULL
medium	NULL
alone	NULL
for	NULL
4	NULL
h	NULL
or	NULL
with	NULL
different	NULL
stimuli	NULL
:	NULL
IL-2	NULL
(	NULL
1000	NULL
units/ml	NULL
)	NULL
(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
or	NULL
IL-2	NULL
(	NULL
1000	NULL
units/m	NULL
!	NULL
)	NULL

plus	NULL
anti-CD3	NULL
(	NULL
C	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
isolated	NULL
and	NULL
electrophoresis	NULL
mobility	NULL
shift	NULL
assays	NULL
were	NULL
performed	NULL
with	NULL
the	NULL
«	NULL
B	NULL
consensus	NULL
oligonucleotide	NULL
(	NULL
A	NULL
)	NULL
and	NULL
the	NULL
oligonucleotide	NULL
that	NULL
corresponds	NULL
to	NULL
the	NULL
«	NULL
B	NULL
sequence	NULL
of	NULL
the	NULL
IL-2R	NULL
«	NULL
gene	NULL
(	NULL
B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

Unlabeled	NULL
oligonucleotides	NULL
were	NULL
added	NULL
at	NULL
100-fold	NULL
excess	NULL
to	NULL
the	NULL
labeled	NULL
probe	NULL
as	NULL
a	NULL
competitor	NULL
.	NULL

+	NULL
,	NULL
the	NULL
stimulation	NULL
of	NULL
T	NULL
cells	NULL
and/or	NULL
the	NULL
addition	NULL
of	NULL
competitor	NULL
to	NULL
the	NULL
EMSA	NULL
.	NULL

titor	NULL
Compe	NULL
!	NULL

a	NULL
“	NULL
Wo	NULL
uy	NULL
Wh	NULL
#	NULL
tn	NULL
l	NULL
o	NULL
bt	NULL
n	NULL
Si	NULL
C.	NULL
TIL	NULL
anti-CDML2	NULL
e	NULL
>	NULL
-	NULL
+	NULL
+	NULL
+	NULL
xB	NULL
IL2Ra	NULL
to	NULL
+	NULL
-	NULL
>	NULL
+	NULL
Oct	NULL
+	NULL
+	NULL
5425	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1994	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

ALTERED	NULL
«	NULL
B	NULL
BINDING	NULL
ACTIVITY	NULL
IN	NULL
T	NULL
CELLS	NULL
While	NULL
IL-2	NULL
or	NULL
cross-linked	NULL
anti-CD3	NULL
antibody	NULL
treatment	NULL
resulted	NULL
in	NULL
activation	NULL
of	NULL
«	NULL
B-binding	NULL
activity	NULL
in	NULL
PBL	NULL
from	NULL
normal	NULL
volunteers	NULL
,	NULL
T	NULL
cells	NULL
derived	NULL
from	NULL
the	NULL
blood	NULL
or	NULL
tumor	NULL
of	NULL
RCC	NULL
patients	NULL
constitutively	NULL
express	NULL
«	NULL
B-binding	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Unstimulated	NULL
T	NULL
cells	NULL
from	NULL
patients	NULL
contained	NULL
a	NULL
DNA-protein	NULL
complex	NULL
which	NULL
was	NULL
comparable	NULL
in	NULL
magnitude	NULL
to	NULL
that	NULL
observed	NULL
with	NULL
activated	NULL
T	NULL
cells	NULL
from	NULL
normal	NULL
individuals	NULL
that	NULL
were	NULL
stimulated	NULL
in	NULL
vitro	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

The	NULL
DNA-protein	NULL
complex	NULL
from	NULL
tumor-derived	NULL
T	NULL
cells	NULL
had	NULL
a	NULL
slightly	NULL
faster	NULL
mobility	NULL
than	NULL
the	NULL
complexes	NULL
from	NULL
autologous	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
and	NULL
from	NULL
activated	NULL
T	NULL
cells	NULL
of	NULL
normal	NULL
individuals	NULL
.	NULL

Stimulating	NULL
patient	NULL
T	NULL
cells	NULL
Experiment	NULL
1	NULL
Experiment	NULL
2	NULL
Patient	NULL
Normal	NULL
Patient	NULL
-	NULL
Normal	NULL
TnL	NULL
PBL	NULL
PBL	NULL
nL	NULL
PBL	NULL
-ACC	NULL
C	NULL
]	NULL
F	NULL
--	NULL
-	NULL
C	NULL
]	NULL
Sumulus	NULL
__	NULL
-	NULL
+	NULL
-	NULL
+	NULL
-	NULL
+	NULL
Stmulus	NULL
|	NULL
-	NULL
+	NULL
-	NULL
+	NULL
wees	NULL
quant	NULL
poe	NULL
ece	NULL
a	NULL
>	NULL
emy	NULL
|	NULL
wus	NULL
+	NULL
Experiment	NULL
3	NULL
Experiment	NULL
4	NULL
Patient	NULL
Normal	NULL
Patient	NULL
_	NULL
Normal	NULL
nL	NULL
PBL	NULL
PBL	NULL
nL	NULL
PBL	NULL
Stimulus	NULL
|	NULL
-	NULL
-	NULL
+	NULL
-	NULL
+	NULL
--	NULL
+	NULL
Stimulus	NULL
|	NULL
-	NULL
=	NULL
+	NULL
-	NULL
+	NULL
«	NULL
emre	NULL
-	NULL
Aghu	NULL
ow	NULL
seme	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Altered	NULL
«	NULL
B-binding	NULL
activity	NULL
is	NULL
a	NULL
consistent	NULL
finding	NULL
in	NULL
TIL	NULL
and	NULL
PBL	NULL
from	NULL
RCC	NULL
patients	NULL
.	NULL

Results	NULL
from	NULL
four	NULL
experiments	NULL
are	NULL
presented	NULL
where	NULL
each	NULL
experiment	NULL
represents	NULL
electrophoresis	NULL
mobility	NULL
shift	NULL
assays	NULL
performed	NULL
on	NULL
nuclear	NULL
extracts	NULL
from	NULL
different	NULL
patients	NULL
and	NULL
normal	NULL
volunteers	NULL
.	NULL

In	NULL
experiments	NULL
1	NULL
,	NULL
3	NULL
,	NULL
and	NULL
4	NULL
,	NULL
T	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
cross-linked	NULL
anti-CD3	NULL
,	NULL
whereas	NULL
in	NULL
experiment	NULL
2	NULL
,	NULL
T	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
IL-2	NULL
(	NULL
1000	NULL
units/ml	NULL
)	NULL
.	NULL

In	NULL
all	NULL
experiments	NULL
nuclear	NULL
extract	NULL
was	NULL
obtained	NULL
after	NULL
4	NULL
h	NULL
of	NULL
stimulation	NULL
.	NULL

Nuclear	NULL
extract	NULL
from	NULL
T	NULL
cells	NULL
cultured	NULL
in	NULL
medium	NULL
alone	NULL
was	NULL
used	NULL
to	NULL
define	NULL
the	NULL
level	NULL
of	NULL
xB-binding	NULL
activity	NULL
of	NULL
unstimulated	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
oligonucleotide	NULL
used	NULL
in	NULL
these	NULL
experiments	NULL
contains	NULL
the	NULL
«	NULL
B	NULL
sequence	NULL
of	NULL
the	NULL
/L-2Rao	NULL
gene	NULL
.	NULL

+	NULL
,	NULL
stimulation	NULL
of	NULL
T	NULL
cells	NULL
;	NULL
-	NULL
,	NULL
cells	NULL
cultured	NULL
in	NULL
medium	NULL
alone	NULL
.	NULL

B	NULL
Cell	NULL
Lymphoma	NULL
PBL	NULL
IL2	NULL
~	NULL
+	NULL
+	NULL
=	NULL
+	NULL
+	NULL
Competitor	NULL
_	NULL
-	NULL
-	NULL
+	NULL
-	NULL
-	NULL
+	NULL
PL	NULL
BCPC	NULL
.	NULL

»	NULL
al	NULL
.-	NULL
bl	NULL
t	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Altered	NULL
xB-binding	NULL
activity	NULL
is	NULL
seen	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
B-cell	NULL
lymphoma	NULL
patients	NULL
.	NULL

T	NULL
cells	NULL
were	NULL
isolated	NULL
from	NULL
the	NULL
peripheral	NULL
blood	NULL
and	NULL
involved	NULL
lymph	NULL
nodes	NULL
of	NULL
a	NULL
patient	NULL
with	NULL
non-Hodgkin	NULL
's	NULL
B-cell	NULL
lymphoma	NULL
(	NULL
diffuse	NULL
large	NULL
noncleaved	NULL
cell	NULL
)	NULL
by	NULL
negative	NULL
selection	NULL
using	NULL
antibodies	NULL
to	NULL
CD19	NULL
(	NULL
B	NULL
cells	NULL
)	NULL
,	NULL
CD56	NULL
(	NULL
natural	NULL
killers	NULL
)	NULL
and	NULL
CD14	NULL
(	NULL
macrophages	NULL
)	NULL
.	NULL

T	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
medium	NULL
alone	NULL
or	NULL
stimulated	NULL
with	NULL
IL-2	NULL
(	NULL
1000	NULL
units/ml	NULL
)	NULL
for	NULL
4	NULL
h.	NULL
Thereafter	NULL
,	NULL
electrophoresis	NULL
mobility	NULL
shift	NULL
assays	NULL
were	NULL
performed	NULL
with	NULL
nuclear	NULL
extracts	NULL
and	NULL
the	NULL
radiolabeled	NULL
oligonucleotide	NULL
corresponding	NULL
to	NULL
the	NULL
xB	NULL
sequence	NULL
of	NULL
the	NULL
/L-2Ra	NULL
gene	NULL
.	NULL

Where	NULL
indicated	NULL
,	NULL
100-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
oligonucleotide	NULL
was	NULL
added	NULL
as	NULL
a	NULL
competitor	NULL
for	NULL
the	NULL
radiolabeled	NULL
probe	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
nodal	NULL
T	NULL
cells	NULL
derived	NULL
from	NULL
two	NULL
additional	NULL
B-cell	NULL
lymphoma	NULL
patients	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

+	NULL
,	NULL
indicates	NULL
stimulation	NULL
of	NULL
T	NULL
cells	NULL
and/or	NULL
the	NULL
addition	NULL
of	NULL
competitor	NULL
to	NULL
EMSA	NULL
.	NULL

with	NULL
IL-2	NULL
or	NULL
anti-CD3	NULL
did	NULL
not	NULL
result	NULL
in	NULL
any	NULL
increase	NULL
in	NULL
the	NULL
intensity	NULL
of	NULL
the	NULL
DNA-protein	NULL
complex	NULL
.	NULL

We	NULL
then	NULL
determined	NULL
whether	NULL
the	NULL
DNA-protein	NULL
complex	NULL
detected	NULL
in	NULL
unstimulated	NULL
T	NULL
cells	NULL
from	NULL
RCC	NULL
patients	NULL
was	NULL
also	NULL
observed	NULL
,	NULL
using	NULL
a	NULL
«	NULL
B	NULL
sequence	NULL
probe	NULL
from	NULL
the	NULL
ZL-2Ra	NULL
gene	NULL
.	NULL

A	NULL
complex	NULL
similar	NULL
to	NULL
that	NULL
seen	NULL
with	NULL
the	NULL
«	NULL
B	NULL
consensus	NULL
sequence	NULL
was	NULL
also	NULL
observed	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
difference	NULL
was	NULL
not	NULL
related	NULL
to	NULL
the	NULL
specific	NULL
motif	NULL
used	NULL
as	NULL
a	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

The	NULL
sequence	NULL
specificity	NULL
of	NULL
the	NULL
binding	NULL
activity	NULL
was	NULL
demonstrated	NULL
by	NULL
performing	NULL
competition	NULL
studies	NULL
with	NULL
100-fold	NULL
excess	NULL
unlabeled	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
the	NULL
«	NULL
B	NULL
sequence	NULL
or	NULL
an	NULL
unrelated	NULL
sequence	NULL
[	NULL
Oct	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
or	NULL
CRE	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
]	NULL
.	NULL

These	NULL
alterations	NULL
were	NULL
observed	NULL
in	NULL
TIL	NULL
and	NULL
PBL	NULL
from	NULL
13	NULL
and	NULL
12	NULL
renal	NULL
patients	NULL
,	NULL
respectively	NULL
.	NULL

Data	NULL
from	NULL
four	NULL
experiments	NULL
are	NULL
presented	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
where	NULL
each	NULL
experiment	NULL
represents	NULL
nuclear	NULL
extract	NULL
derived	NULL
from	NULL
a	NULL
different	NULL
patient	NULL
and	NULL
normal	NULL
healthy	NULL
volunteer	NULL
.	NULL

The	NULL
possibility	NULL
that	NULL
nuclear	NULL
«	NULL
B-binding	NULL
activity	NULL
in	NULL
unstimulated	NULL
T	NULL
cells	NULL
from	NULL
RCC	NULL
patients	NULL
was	NULL
the	NULL
result	NULL
of	NULL
cell	NULL
isolation	NULL
or	NULL
culturing	NULL
procedures	NULL
was	NULL
also	NULL
examined	NULL
.	NULL

A	NULL
comparison	NULL
was	NULL
made	NULL
between	NULL
the	NULL
level	NULL
of	NULL
«	NULL
xB	NULL
sequence-binding	NULL
activity	NULL
in	NULL
freshly	NULL
isolated	NULL
T	NULL
cells	NULL
to	NULL
that	NULL
in	NULL
T	NULL
cells	NULL
that	NULL
had	NULL
been	NULL
incubated	NULL
in	NULL
medium	NULL
alone	NULL
for	NULL
4	NULL
h.	NULL
Comparable	NULL
levels	NULL
of	NULL
NF-KB	NULL
complexes	NULL
were	NULL
detected	NULL
from	NULL
both	NULL
T	NULL
cell	NULL
populations	NULL
,	NULL
suggesting	NULL
that	NULL
short-term	NULL
culture	NULL
did	NULL
not	NULL
account	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
«	NULL
B-binding	NULL
activity	NULL
in	NULL
unstimulated	NULL
T	NULL
cells	NULL
from	NULL
RCC	NULL
patients	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
enzyme	NULL
solution	NULL
used	NULL
to	NULL
obtain	NULL
T	NULL
cells	NULL
from	NULL
the	NULL
tumor	NULL
did	NULL
not	NULL
appear	NULL
to	NULL
induce	NULL
NF-	NULL
«	NULL
B	NULL
nuclear	NULL
translocation	NULL
since	NULL
nuclear	NULL
«	NULL
B-binding	NULL
activity	NULL
was	NULL
not	NULL
detected	NULL
after	NULL
enzymatic	NULL
treatment	NULL
of	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
obtained	NULL
from	NULL
normal	NULL
individuals	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

We	NULL
also	NULL
determined	NULL
whether	NULL
T	NULL
cells	NULL
derived	NULL
from	NULL
a	NULL
different	NULL
type	NULL
of	NULL
tumor	NULL
would	NULL
have	NULL
similar	NULL
alterations	NULL
in	NULL
«	NULL
B-binding	NULL
activity	NULL
.	NULL

For	NULL
these	NULL
experiments	NULL
,	NULL
T	NULL
cells	NULL
were	NULL
isolated	NULL
from	NULL
involved	NULL
lymph	NULL
nodes	NULL
5426	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1994	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

ALTERED	NULL
«	NULL
B	NULL
BINDING	NULL
ACTIVITY	NULL
IN	NULL
T	NULL
CELLS	NULL
A	NULL
.	NULL

Normal	NULL
RCC	NULL
PBL	NULL
-	NULL
PBL	NULL
m	NULL
s	NULL
ms	NULL
-as	NULL
p65	NULL
--	NULL
cam	NULL
ame	NULL
m-	NULL
-	NULL
-G-	NULL
p50	NULL
B	NULL
.	NULL

Normal	NULL
RCC	NULL
PBL	NULL
TTL	NULL
m	NULL
-s	NULL
m	NULL
-~	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

T	NULL
cells	NULL
from	NULL
RCC	NULL
patients	NULL
fail	NULL
to	NULL
express	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
in	NULL
the	NULL
nucleus	NULL
after	NULL
stimulation	NULL
in	NULL
vitro	NULL
.	NULL

(	NULL
A	NULL
)	NULL
T	NULL
cells	NULL
from	NULL
the	NULL
peripheral	NULL
blood	NULL
of	NULL
a	NULL
RCC	NULL
patient	NULL
and	NULL
a	NULL
healthy	NULL
donor	NULL
were	NULL
incubated	NULL
in	NULL
vitro	NULL
for	NULL
4	NULL
h	NULL
in	NULL
either	NULL
medium	NULL
alone	NULL
(	NULL
m	NULL
)	NULL
or	NULL
with	NULL
the	NULL
stimulus	NULL
(	NULL
s	NULL
)	NULL
,	NULL
IL-2	NULL
(	NULL
1000	NULL
units/ml	NULL
)	NULL
plus	NULL
cross-linked	NULL
anti-CD3	NULL
antibody	NULL
.	NULL

Thereafter	NULL
,	NULL
cells	NULL
were	NULL
lysed	NULL
and	NULL
equivalent	NULL
amounts	NULL
of	NULL
nuclear	NULL
protein	NULL
(	NULL
15	NULL
ug	NULL
)	NULL
were	NULL
run	NULL
on	NULL
sodium	NULL
dodecyl	NULL
sulfate-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
gels	NULL
.	NULL

Western	NULL
blotting	NULL
was	NULL
then	NULL
performed	NULL
using	NULL
anti-bodies	NULL
to	NULL
NF-	NULL
«	NULL
B1	NULL
(	NULL
p50	NULL
)	NULL
and	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
as	NULL
described	NULL
in	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

(	NULL
B	NULL
)	NULL
Similar	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
TIL	NULL
from	NULL
another	NULL
RCC	NULL
patient	NULL
.	NULL

For	NULL
comparison	NULL
are	NULL
results	NULL
from	NULL
T	NULL
cells	NULL
isolated	NULL
from	NULL
a	NULL
healthy	NULL
donor	NULL
(	NULL
different	NULL
than	NULL
the	NULL
one	NULL
presented	NULL
in	NULL
A	NULL
)	NULL
of	NULL
patients	NULL
with	NULL
non-Hodgkin	NULL
's	NULL
B	NULL
cell	NULL
lymphomas	NULL
(	NULL
n	NULL
=	NULL
4	NULL
)	NULL
by	NULL
negative	NULL
selection	NULL
.	NULL

Substantial	NULL
«	NULL
B-binding	NULL
activity	NULL
was	NULL
observed	NULL
in	NULL
nuclear	NULL
extract	NULL
from	NULL
nonmalignant	NULL
T	NULL
cells	NULL
derived	NULL
from	NULL
the	NULL
B	NULL
cell	NULL
lymphoma	NULL
patients	NULL
.	NULL

Stimulation	NULL
with	NULL
IL-2	NULL
or	NULL
anti-CD3	NULL
antibody	NULL
did	NULL
not	NULL
increase	NULL
the	NULL
magnitude	NULL
of	NULL
the	NULL
complex	NULL
detected	NULL
by	NULL
electrophoresis	NULL
mobility	NULL
shift	NULL
assay	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
representative	NULL
data	NULL
)	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
altered	NULL
«	NULL
B-binding	NULL
activity	NULL
is	NULL
present	NULL
in	NULL
another	NULL
tumor	NULL
type	NULL
.	NULL

Whether	NULL
abnormal	NULL
«	NULL
B-binding	NULL
activity	NULL
is	NULL
a	NULL
common	NULL
feature	NULL
of	NULL
T	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
cancer	NULL
will	NULL
require	NULL
analysis	NULL
of	NULL
T	NULL
cells	NULL
from	NULL
multiple	NULL
histological	NULL
types	NULL
of	NULL
tumors	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
«	NULL
B-specific	NULL
Binding	NULL
Proteins	NULL
in	NULL
T	NULL
Cells	NULL
of	NULL
RCC	NULL
Patients	NULL
.	NULL

Western	NULL
blotting	NULL
was	NULL
performed	NULL
to	NULL
identify	NULL
which	NULL
of	NULL
the	NULL
«	NULL
B-specific	NULL
binding	NULL
proteins	NULL
are	NULL
present	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
T	NULL
cells	NULL
from	NULL
RCC	NULL
patients	NULL
before	NULL
and	NULL
after	NULL
stimulation	NULL
.	NULL

To	NULL
detect	NULL
NF-	NULL
«	NULL
B1	NULL
and	NULL
RelA	NULL
in	NULL
nuclei	NULL
,	NULL
T	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
medium	NULL
alone	NULL
or	NULL
with	NULL
cross-linked	NULL
anti-CD3/IL2	NULL
(	NULL
stimulus	NULL
)	NULL
for	NULL
4	NULL
h.	NULL
Both	NULL
NF-	NULL
«	NULL
B1	NULL
and	NULL
RelA	NULL
were	NULL
present	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
T	NULL
cells	NULL
of	NULL
healthy	NULL
individuals	NULL
,	NULL
and	NULL
their	NULL
levels	NULL
increased	NULL
significantly	NULL
after	NULL
in	NULL
vitro	NULL
stimulation	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
T	NULL
cells	NULL
from	NULL
the	NULL
peripheral	NULL
blood	NULL
and	NULL
tumor	NULL
of	NULL
RCC	NULL
patients	NULL
expressed	NULL
abundant	NULL
NF-	NULL
«	NULL
B1	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
in	NULL
vitro	NULL
stimulation	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
A	NULL
and	NULL
B	NULL
,	NULL
Lanes	NULL
m	NULL
)	NULL
and	NULL
this	NULL
level	NULL
did	NULL
not	NULL
increase	NULL
after	NULL
T-cell	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
A	NULL
and	NULL
B	NULL
,	NULL
Lanes	NULL
s	NULL
)	NULL
We	NULL
found	NULL
no	NULL
expression	NULL
of	NULL
RelA	NULL
in	NULL
T-cell	NULL
nuclear	NULL
extract	NULL
of	NULL
RCC	NULL
patients	NULL
before	NULL
and	NULL
after	NULL
activation	NULL
by	NULL
Western	NULL
blotting	NULL
.	NULL

However	NULL
,	NULL
Western	NULL
analysis	NULL
of	NULL
cytoplasmic	NULL
extract	NULL
from	NULL
the	NULL
same	NULL
samples	NULL
demonstrated	NULL
that	NULL
RelA	NULL
was	NULL
present	NULL
but	NULL
not	NULL
translocating	NULL
to	NULL
the	NULL
nucleus	NULL
after	NULL
stimulation	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
observed	NULL
with	NULL
T	NULL
cells	NULL
from	NULL
the	NULL
peripheral	NULL
blood	NULL
of	NULL
4	NULL
other	NULL
RCC	NULL
patients	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

DISCUSSION	NULL
The	NULL
results	NULL
presented	NULL
here	NULL
show	NULL
that	NULL
T	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
renal	NULL
cell	NULL
carcinoma	NULL
have	NULL
alterations	NULL
in	NULL
«	NULL
B-specific	NULL
DNA-binding	NULL
activity	NULL
as	NULL
compared	NULL
to	NULL
T	NULL
cells	NULL
from	NULL
the	NULL
peripheral	NULL
blood	NULL
of	NULL
normal	NULL
individuals	NULL
.	NULL

Substantial	NULL
«	NULL
B-binding	NULL
activity	NULL
is	NULL
detected	NULL
in	NULL
these	NULL
cells	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
stimulation	NULL
and	NULL
this	NULL
complex	NULL
is	NULL
composed	NULL
mostly	NULL
of	NULL
NF-	NULL
«	NULL
B1	NULL
(	NULL
p50	NULL
)	NULL
.	NULL

Stimulation	NULL
with	NULL
either	NULL
IL-2	NULL
or	NULL
anti-CD3	NULL
antibody	NULL
did	NULL
not	NULL
induce	NULL
nuclear	NULL
expression	NULL
of	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
in	NULL
patient	NULL
T	NULL
cells	NULL
there	NULL
is	NULL
no	NULL
induction	NULL
of	NULL
a	NULL
normal	NULL
NF-	NULL
«	NULL
B	NULL
complex	NULL
(	NULL
p50/p65	NULL
)	NULL
after	NULL
in	NULL
vitro	NULL
stimulation	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
substantial	NULL
«	NULL
B-binding	NULL
activity	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
T	NULL
cells	NULL
of	NULL
RCC	NULL
patients	NULL
without	NULL
prior	NULL
stimulation	NULL
is	NULL
distinct	NULL
from	NULL
what	NULL
is	NULL
normally	NULL
observed	NULL
with	NULL
T	NULL
cells	NULL
from	NULL
healthy	NULL
individuals	NULL
where	NULL
little	NULL
or	NULL
no	NULL
binding	NULL
activity	NULL
is	NULL
detected	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
stimulation	NULL
(	NULL
35	NULL
,	NULL
38	NULL
)	NULL
.	NULL

The	NULL
constitutive	NULL
expression	NULL
of	NULL
«	NULL
B-binding	NULL
activity	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
the	NULL
peripheral	NULL
blood	NULL
and	NULL
tumors	NULL
of	NULL
these	NULL
patients	NULL
suggests	NULL
that	NULL
the	NULL
abnormal	NULL
expression	NULL
of	NULL
«	NULL
B	NULL
activity	NULL
represents	NULL
a	NULL
generalized	NULL
event	NULL
which	NULL
affects	NULL
much	NULL
of	NULL
the	NULL
host	NULL
T-cell	NULL
population	NULL
.	NULL

We	NULL
also	NULL
noticed	NULL
in	NULL
the	NULL
majority	NULL
of	NULL
experiments	NULL
that	NULL
the	NULL
«	NULL
B-binding	NULL
complex	NULL
isolated	NULL
from	NULL
TIL	NULL
migrated	NULL
faster	NULL
than	NULL
the	NULL
complex	NULL
from	NULL
PBL	NULL
of	NULL
RCC	NULL
patients	NULL
.	NULL

What	NULL
accounts	NULL
for	NULL
the	NULL
difference	NULL
in	NULL
migration	NULL
rate	NULL
is	NULL
not	NULL
known	NULL
since	NULL
NF-	NULL
«	NULL
B1	NULL
is	NULL
the	NULL
predominant	NULL
DNA-binding	NULL
protein	NULL
isolated	NULL
from	NULL
both	NULL
sources	NULL
of	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Previous	NULL
studies	NULL
have	NULL
reported	NULL
NF-	NULL
«	NULL
B1	NULL
expression	NULL
in	NULL
resting	NULL
lymphocytes	NULL
and	NULL
in	NULL
certain	NULL
T	NULL
cell	NULL
lines	NULL
(	NULL
35	NULL
,	NULL
39	NULL
,	NULL
40	NULL
)	NULL
.	NULL

NF-	NULL
«	NULL
B1	NULL
in	NULL
the	NULL
nucleus	NULL
of	NULL
T	NULL
cells	NULL
may	NULL
translate	NULL
into	NULL
suppression	NULL
rather	NULL
than	NULL
induction	NULL
of	NULL
gene	NULL
expression	NULL
.	NULL

In	NULL
a	NULL
nontransformed	NULL
CD4*	NULL
T-cell	NULL
clone	NULL
the	NULL
expression	NULL
of	NULL
NF-	NULL
«	NULL
B1	NULL
homodimers	NULL
in	NULL
the	NULL
nucleus	NULL
was	NULL
associated	NULL
with	NULL
suppression	NULL
of	NULL
IL-2	NULL
transcription	NULL
(	NULL
40	NULL
)	NULL
.	NULL

Following	NULL
antigen	NULL
stimulation	NULL
the	NULL
induction	NULL
of	NULL
IL-2	NULL
gene	NULL
expression	NULL
correlated	NULL
with	NULL
a	NULL
reduction	NULL
in	NULL
NF-	NULL
«	NULL
B1	NULL
homodimers	NULL
and	NULL
a	NULL
concomitant	NULL
increase	NULL
in	NULL
the	NULL
NF-	NULL
«	NULL
B1/ReIA	NULL
heterodimer	NULL
(	NULL
40	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
overexpression	NULL
of	NULL
NF-	NULL
«	NULL
B1	NULL
in	NULL
T	NULL
cells	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
repress	NULL
IL-2	NULL
promoter	NULL
activity	NULL
(	NULL
40	NULL
)	NULL
.	NULL

Whether	NULL
the	NULL
increase	NULL
in	NULL
nuclear	NULL
NF-	NULL
«	NULL
B1	NULL
suppresses	NULL
gene	NULL
expression	NULL
following	NULL
antigen	NULL
stimulation	NULL
remains	NULL
to	NULL
be	NULL
determined	NULL
.	NULL

Our	NULL
findings	NULL
demonstrate	NULL
that	NULL
at	NULL
least	NULL
one	NULL
member	NULL
of	NULL
the	NULL
Rel	NULL
homology	NULL
family	NULL
was	NULL
not	NULL
inducible	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
the	NULL
RCC	NULL
patients	NULL
.	NULL

Unlike	NULL
activated	NULL
T	NULL
cells	NULL
from	NULL
normal	NULL
individuals	NULL
,	NULL
T	NULL
cells	NULL
from	NULL
RCC	NULL
patients	NULL
had	NULL
little	NULL
or	NULL
no	NULL
detectable	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
in	NULL
their	NULL
nuclear	NULL
extracts	NULL
after	NULL
stimulation	NULL
.	NULL

Whether	NULL
other	NULL
members	NULL
of	NULL
the	NULL
«	NULL
B/Re	NULL
!	NULL

family	NULL
proteins	NULL
such	NULL
as	NULL
c-Rel	NULL
(	NULL
41	NULL
)	NULL
are	NULL
expressed	NULL
in	NULL
the	NULL
nucleus	NULL
of	NULL
T	NULL
cells	NULL
from	NULL
RCC	NULL
patients	NULL
after	NULL
in	NULL
vitro	NULL
stimulation	NULL
remains	NULL
to	NULL
be	NULL
determined	NULL
.	NULL

The	NULL
mechanism	NULL
(	NULL
s	NULL
)	NULL
responsible	NULL
for	NULL
the	NULL
inability	NULL
to	NULL
induce	NULL
«	NULL
B-binding	NULL
activity	NULL
is	NULL
not	NULL
known	NULL
but	NULL
may	NULL
relate	NULL
to	NULL
defects	NULL
in	NULL
upstream	NULL
signaling	NULL
elements	NULL
(	NULL
34	NULL
)	NULL
.	NULL

The	NULL
release	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
from	NULL
IxBa	NULL
in	NULL
the	NULL
cytoplasm	NULL
and	NULL
the	NULL
translocation	NULL
of	NULL
xB-binding	NULL
activity	NULL
into	NULL
the	NULL
nucleus	NULL
may	NULL
involve	NULL
the	NULL
phosphorylation	NULL
of	NULL
IxBa	NULL
(	NULL
34	NULL
,	NULL
42	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
studies	NULL
demonstrate	NULL
that	NULL
the	NULL
phosphorylation	NULL
of	NULL
IxBa	NULL
is	NULL
mediated	NULL
by	NULL
PKC	NULL
(	NULL
34	NULL
,	NULL
42	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
protein	NULL
tyrosine	NULL
kinases	NULL
associated	NULL
with	NULL
the	NULL
TCR/CD3	NULL
complex	NULL
are	NULL
linked	NULL
to	NULL
PKC	NULL
activation	NULL
in	NULL
that	NULL
they	NULL
are	NULL
responsible	NULL
for	NULL
the	NULL
phosphorylation	NULL
of	NULL
phospholipase	NULL
C-y1	NULL
(	NULL
23	NULL
,	NULL
43	NULL
)	NULL
.	NULL

The	NULL
activation	NULL
of	NULL
phospholipase	NULL
C-y1	NULL
causes	NULL
the	NULL
hydrolysis	NULL
of	NULL
phos-phatidylinositol	NULL
4,5-bisphosphate	NULL
,	NULL
resulting	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
dia-cyglycerol	NULL
which	NULL
in	NULL
turn	NULL
activates	NULL
PKC	NULL
(	NULL
43	NULL
)	NULL
.	NULL

We	NULL
have	NULL
demonstrated	NULL
that	NULL
T	NULL
cells	NULL
from	NULL
RCC	NULL
patients	NULL
are	NULL
missing	NULL
TCRCL	NULL
,	NULL
p56	NULL
``	NULL
,	NULL
and	NULL
p59	NULL
``	NULL
(	NULL
21	NULL
)	NULL
.	NULL

*	NULL
The	NULL
absence	NULL
of	NULL
these	NULL
signaling	NULL
elements	NULL
in	NULL
T	NULL
cells	NULL
may	NULL
prevent	NULL
normal	NULL
activation	NULL
and	NULL
the	NULL
phosphorylation	NULL
of	NULL
IxBa	NULL
,	NULL
thus	NULL
inhibiting	NULL
the	NULL
translocation	NULL
of	NULL
p50/p65	NULL
complex	NULL
into	NULL
the	NULL
nucleus	NULL
.	NULL

This	NULL
possibility	NULL
is	NULL
supported	NULL
by	NULL
Western	NULL
blotting	NULL
experiments	NULL
where	NULL
we	NULL
have	NULL
demonstrated	NULL
that	NULL
while	NULL
RelA	NULL
does	NULL
not	NULL
translocate	NULL
to	NULL
the	NULL
nucleus	NULL
following	NULL
activation	NULL
of	NULL
patient	NULL
T	NULL
cells	NULL
,	NULL
it	NULL
is	NULL
present	NULL
in	NULL
the	NULL
cytoplasm	NULL
along	NULL
with	NULL
IxBa	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

*	NULL
Finke	NULL
et	NULL
al	NULL
.	NULL

,	NULL
manuscript	NULL
in	NULL
preparation	NULL
.	NULL

5427	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1994	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

ALTERED	NULL
«	NULL
B	NULL
BINDING	NULL
ACTIVITY	NULL
IN	NULL
T	NULL
CELLS	NULL
The	NULL
constitutive	NULL
expression	NULL
of	NULL
high	NULL
levels	NULL
of	NULL
NF-	NULL
«	NULL
B1	NULL
and	NULL
failure	NULL
to	NULL
induce	NULL
other	NULL
members	NULL
of	NULL
the	NULL
«	NULL
B/Rel	NULL
family	NULL
of	NULL
proteins	NULL
following	NULL
the	NULL
stimulation	NULL
of	NULL
T	NULL
cells	NULL
from	NULL
RCC	NULL
patients	NULL
may	NULL
have	NULL
a	NULL
negative	NULL
impact	NULL
on	NULL
T-cell	NULL
function	NULL
.	NULL

We	NULL
reported	NULL
previously	NULL
that	NULL
TIL	NULL
from	NULL
patients	NULL
with	NULL
RCC	NULL
have	NULL
a	NULL
proliferative	NULL
defect	NULL
when	NULL
compared	NULL
to	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
(	NULL
18	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
proliferative	NULL
defect	NULL
of	NULL
TIL	NULL
may	NULL
not	NULL
be	NULL
related	NULL
to	NULL
the	NULL
altered	NULL
expression	NULL
of	NULL
«	NULL
B-binding	NULL
activity	NULL
since	NULL
the	NULL
inducibility	NULL
of	NULL
«	NULL
B-binding	NULL
activity	NULL
is	NULL
reversible	NULL
after	NULL
in	NULL
vitro	NULL
culture	NULL
,	NULL
whereas	NULL
the	NULL
defect	NULL
in	NULL
proliferation	NULL
is	NULL
not	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
proliferative	NULL
defect	NULL
is	NULL
present	NULL
in	NULL
TIL	NULL
but	NULL
not	NULL
PBL	NULL
,	NULL
whereas	NULL
T	NULL
cells	NULL
from	NULL
both	NULL
sources	NULL
display	NULL
altered	NULL
«	NULL
B-binding	NULL
activity	NULL
.	NULL

It	NULL
may	NULL
be	NULL
that	NULL
the	NULL
altered	NULL
«	NULL
B-binding	NULL
activity	NULL
is	NULL
related	NULL
to	NULL
depressed	NULL
production	NULL
of	NULL
cytokines	NULL
.	NULL

Re-cently	NULL
,	NULL
it	NULL
was	NULL
reported	NULL
that	NULL
splenic	NULL
T	NULL
cells	NULL
from	NULL
mice	NULL
bearing	NULL
the	NULL
renal	NULL
cell	NULL
carcinoma	NULL
line	NULL
RENCA	NULL
have	NULL
altered	NULL
expression	NULL
of	NULL
the	NULL
«	NULL
B/Rel	NULL
family	NULL
of	NULL
proteins	NULL
,	NULL
which	NULL
correlated	NULL
with	NULL
reduced	NULL
expression	NULL
of	NULL
IFN-y	NULL
mRNA	NULL
(	NULL
44	NULL
)	NULL
.	NULL

The	NULL
abnormal	NULL
«	NULL
B-binding	NULL
activity	NULL
in	NULL
TIL	NULL
from	NULL
RCC	NULL
patients	NULL
is	NULL
consistent	NULL
with	NULL
no	NULL
or	NULL
infrequent	NULL
expression	NULL
of	NULL
cytokine	NULL
mRNA	NULL
(	NULL
IL-2	NULL
or	NULL
IFN-y	NULL
)	NULL
(	NULL
45	NULL
)	NULL
or	NULL
IL-2Ra	NULL
mRNA	NULL
(	NULL
18	NULL
)	NULL
,	NULL
which	NULL
is	NULL
usually	NULL
associated	NULL
with	NULL
T-cell	NULL
activation	NULL
.	NULL

However	NULL
,	NULL
when	NULL
activated	NULL
in	NULL
vitro	NULL
,	NULL
TIL	NULL
from	NULL
RCC	NULL
patients	NULL
are	NULL
capable	NULL
of	NULL
producing	NULL
IL-2	NULL
and	NULL
IFN-y	NULL
,	NULL
although	NULL
the	NULL
level	NULL
of	NULL
production	NULL
may	NULL
be	NULL
low	NULL
relative	NULL
to	NULL
T	NULL
cells	NULL
from	NULL
normal	NULL
individuals	NULL
(	NULL
46	NULL
)	NULL
.°	NULL
Additional	NULL
studies	NULL
to	NULL
measure	NULL
the	NULL
rate	NULL
of	NULL
IFN-y	NULL
(	NULL
and	NULL
IL-2	NULL
)	NULL
gene	NULL
transcription	NULL
between	NULL
T	NULL
cells	NULL
from	NULL
normal	NULL
individuals	NULL
and	NULL
RCC	NULL
patients	NULL
are	NULL
needed	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
alterations	NULL
in	NULL
«	NULL
B-binding	NULL
activity	NULL
are	NULL
related	NULL
to	NULL
impaired	NULL
cytokine	NULL
production	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Mulé	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
Yang	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Shu	NULL
,	NULL
S.	NULL
,	NULL
Lafreniere	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Rosenberg	NULL
,	NULL
S.	NULL
A	NULL
.	NULL

Identification	NULL
of	NULL
cellular	NULL
mechanisms	NULL
operational	NULL
in	NULL
vivo	NULL
during	NULL
the	NULL
regression	NULL
of	NULL
established	NULL
pulmonary	NULL
metastases	NULL
by	NULL
the	NULL
systemic	NULL
administration	NULL
of	NULL
high-dose	NULL
recombinant	NULL
interleukin-2	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
739	NULL
;	NULL
285-294	NULL
,	NULL
1987	NULL
.	NULL

2	NULL
.	NULL

Rosenberg	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Spiess	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Lafreniere	NULL
,	NULL
R.	NULL
A	NULL
new	NULL
approach	NULL
to	NULL
the	NULL
adoptive	NULL
immunotherapy	NULL
of	NULL
cancer	NULL
with	NULL
tumor-infiltrating	NULL
lymphocytes	NULL
.	NULL

Science	NULL
(	NULL
Washington	NULL
DC	NULL
)	NULL
,	NULL
233	NULL
:	NULL
1318-1321	NULL
,	NULL
1986	NULL
.	NULL

3	NULL
.	NULL

Spiess	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Yang	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
and	NULL
Rosenberg	NULL
,	NULL
S.	NULL
A	NULL
.	NULL

In	NULL
vivo	NULL
antitumor	NULL
activity	NULL
of	NULL
tumor-infiltrating	NULL
lymphocytes	NULL
expanded	NULL
in	NULL
recombinant	NULL
interleukin	NULL
2	NULL
.	NULL

J.	NULL
Natl	NULL
.	NULL

Cancer	NULL
Inst	NULL
.	NULL

,	NULL
75	NULL
:	NULL
1067-1075	NULL
,	NULL
1987	NULL
.	NULL

4	NULL
.	NULL

Topalian	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Solomon	NULL
,	NULL
D.	NULL
,	NULL
Avis	NULL
,	NULL
F.	NULL
F.	NULL
,	NULL
Chang	NULL
,	NULL
A.	NULL
E.	NULL
,	NULL
Freerksen	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
Linchan	NULL
,	NULL
W.	NULL
M.	NULL
,	NULL
Lotze	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
Robertson	NULL
,	NULL
C.	NULL
N.	NULL
,	NULL
Seipp	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Simon	NULL
,	NULL
P.	NULL
,	NULL
Simpson	NULL
,	NULL
C.	NULL
G.	NULL
,	NULL
and	NULL
Rosenberg	NULL
,	NULL
S.	NULL
A.	NULL
Immunotherapy	NULL
of	NULL
patients	NULL
with	NULL
advanced	NULL
cancer	NULL
using	NULL
tumor-infiltrating	NULL
lymphocytes	NULL
and	NULL
recombinant	NULL
interleukin-2	NULL
:	NULL
a	NULL
pilot	NULL
study	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Oncol	NULL
.	NULL

,	NULL
6	NULL
:	NULL
839-853	NULL
,	NULL
1988	NULL
.	NULL

5	NULL
.	NULL

Whiteside	NULL
,	NULL
T.	NULL
L.	NULL
,	NULL
Miescher	NULL
,	NULL
S.	NULL
,	NULL
Mulimann	NULL
,	NULL
J.	NULL
,	NULL
Moretta	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Von	NULL
Fliedner	NULL
,	NULL
V.	NULL
Separation	NULL
,	NULL
phenotyping	NULL
and	NULL
limiting	NULL
dilution	NULL
analysis	NULL
of	NULL
T-lymphocytes	NULL
infiltrating	NULL
human	NULL
solid	NULL
tumors	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
37	NULL
:	NULL
803-811	NULL
,	NULL
1986	NULL
.	NULL

6	NULL
.	NULL

Itoh	NULL
,	NULL
K.	NULL
,	NULL
Tilden	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
,	NULL
and	NULL
Balch	NULL
,	NULL
C.	NULL
M.	NULL
Interleukin	NULL
2	NULL
activation	NULL
of	NULL
cytotoxic	NULL
T-lymphocytes	NULL
infiltrating	NULL
into	NULL
human	NULL
metastatic	NULL
melanomas	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
46	NULL
:	NULL
3011-3017	NULL
,	NULL
1986	NULL
.	NULL

7	NULL
.	NULL

Muul	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
Spiess	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Director	NULL
,	NULL
E.	NULL
P.	NULL
,	NULL
and	NULL
Rosenberg	NULL
,	NULL
S.	NULL
A	NULL
.	NULL

Identification	NULL
of	NULL
specific	NULL
cytolytic	NULL
immune	NULL
responses	NULL
against	NULL
autologous	NULL
tumor	NULL
in	NULL
humans	NULL
bearing	NULL
malignant	NULL
melanoma	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
138	NULL
:	NULL
989-995	NULL
,	NULL
1987	NULL
.	NULL

8	NULL
.	NULL

Ioannides	NULL
,	NULL
C.	NULL
G.	NULL
,	NULL
Rashed	NULL
,	NULL
S.	NULL
,	NULL
Fisk	NULL
,	NULL
B.	NULL
,	NULL
Fan	NULL
,	NULL
D.	NULL
,	NULL
Itoh	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Freedman	NULL
,	NULL
R.	NULL
S.	NULL
Lymphocytes	NULL
infiltrating	NULL
ovarian	NULL
malignant	NULL
ascites	NULL
:	NULL
modulation	NULL
of	NULL
IL2-induced	NULL
proliferation	NULL
by	NULL
IL4	NULL
and	NULL
selective	NULL
increase	NULL
in	NULL
CD8*	NULL
T	NULL
cells	NULL
by	NULL
TNF-a	NULL
.	NULL

Lymphokine	NULL
Cytokine	NULL
Res	NULL
.	NULL

,	NULL
10	NULL
:	NULL
307-315	NULL
,	NULL
1991	NULL
.	NULL

9	NULL
.	NULL

Letesjier	NULL
,	NULL
E.	NULL
M.	NULL
,	NULL
Heo	NULL
,	NULL
D.	NULL
S.	NULL
,	NULL
Okarma	NULL
,	NULL
T.	NULL
,	NULL
Johnson	NULL
,	NULL
J.	NULL
T.	NULL
,	NULL
Herberman	NULL
,	NULL
R.	NULL
B.	NULL
,	NULL
and	NULL
Whiteside	NULL
,	NULL
T.	NULL
L.	NULL
Enrichment	NULL
in	NULL
tumor-reactive	NULL
CD8*	NULL
T-lymphocytes	NULL
by	NULL
positive	NULL
selection	NULL
from	NULL
the	NULL
blood	NULL
and	NULL
lyriph	NULL
nodes	NULL
of	NULL
patients	NULL
with	NULL
head	NULL
and	NULL
neck	NULL
cancer	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
57	NULL
:	NULL
3891-3899	NULL
,	NULL
1991	NULL
.	NULL

10	NULL
.	NULL

Jerome	NULL
,	NULL
K.	NULL
R.	NULL
,	NULL
Brand	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
Bendt	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Boyer	NULL
,	NULL
C.	NULL
,	NULL
Taylor-Papadimtriou	NULL
,	NULL
J.	NULL
,	NULL
McKenzie	NULL
,	NULL
I.	NULL
,	NULL
Bast	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Finn	NULL
,	NULL
O.	NULL
Cytotoxic	NULL
T-lymphocytes	NULL
derived	NULL
from	NULL
patients	NULL
with	NULL
breast	NULL
adenocarcinoma	NULL
recognize	NULL
an	NULL
epitope	NULL
present	NULL
on	NULL
the	NULL
protein	NULL
core	NULL
of	NULL
a	NULL
mucin	NULL
molecule	NULL
preferentially	NULL
expressed	NULL
by	NULL
malignant	NULL
cells	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
57	NULL
:	NULL
2908-2916	NULL
,	NULL
1991	NULL
.	NULL

11	NULL
.	NULL

Broder	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Waldmann	NULL
,	NULL
T.	NULL
A	NULL
.	NULL

The	NULL
suppressor-cell	NULL
network	NULL
in	NULL
cancer	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
299	NULL
:	NULL
1281-1284	NULL
,	NULL
1978	NULL
.	NULL

12	NULL
.	NULL

Hersh	NULL
,	NULL
E.	NULL
M.	NULL
,	NULL
and	NULL
Oppenheim	NULL
,	NULL
J.	NULL
J	NULL
.	NULL

Impaired	NULL
in	NULL
vitro	NULL
lymphocyte	NULL
transformation	NULL
in	NULL
Hodgkin	NULL
's	NULL
disease	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
273	NULL
:	NULL
1006-1012	NULL
,	NULL
1965	NULL
.	NULL

13	NULL
.	NULL

Oliver	NULL
,	NULL
R.	NULL
T.	NULL
,	NULL
and	NULL
Nouri	NULL
,	NULL
A.	NULL
M.	NULL
T	NULL
cell	NULL
immune	NULL
response	NULL
to	NULL
cancer	NULL
in	NULL
humans	NULL
and	NULL
its	NULL
relevance	NULL
for	NULL
immunodiagnosis	NULL
and	NULL
therapy	NULL
.	NULL

Cancer	NULL
Surv	NULL
.	NULL

,	NULL
73	NULL
:	NULL
173-204	NULL
,	NULL
1992	NULL
.	NULL

*	NULL
Li	NULL
er	NULL
al	NULL
.	NULL

,	NULL
manuscript	NULL
in	NULL
preparation	NULL
.	NULL

©	NULL
Finke	NULL
er	NULL
al	NULL
.	NULL

,	NULL
unpublished	NULL
data	NULL
.	NULL

14	NULL
.	NULL

Roszman	NULL
,	NULL
T.	NULL
,	NULL
Elliott	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Brooks	NULL
,	NULL
V.	NULL
V.	NULL
Modulation	NULL
of	NULL
T-cell	NULL
function	NULL
by	NULL
gliomas	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
,	NULL
12	NULL
:	NULL
370-374	NULL
,	NULL
1991	NULL
.	NULL

15	NULL
.	NULL

Miescher	NULL
,	NULL
S.	NULL
,	NULL
Whiteside	NULL
,	NULL
T.	NULL
L.	NULL
,	NULL
Carrel	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Von	NULL
Fliedner	NULL
,	NULL
V.	NULL
Functional	NULL
properties	NULL
of	NULL
tumor-infiltrating	NULL
and	NULL
blood	NULL
lymphocytes	NULL
in	NULL
patients	NULL
with	NULL
solid	NULL
tumors	NULL
:	NULL
effects	NULL
of	NULL
tumor	NULL
cells	NULL
and	NULL
their	NULL
supernatants	NULL
on	NULL
proliferative	NULL
responses	NULL
of	NULL
lymphocytes	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
136	NULL
;	NULL
1899-1907	NULL
,	NULL
1986	NULL
.	NULL

16	NULL
.	NULL

Miescher	NULL
,	NULL
S.	NULL
,	NULL
Stoeck	NULL
,	NULL
M.	NULL
,	NULL
Qiao	NULL
,	NULL
L.	NULL
,	NULL
Barras	NULL
,	NULL
C.	NULL
,	NULL
Barrelet	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Von	NULL
Fliedner	NULL
,	NULL
V.	NULL
Proliferative	NULL
and	NULL
cytolytic	NULL
potentials	NULL
of	NULL
purified	NULL
human	NULL
tumor-infiltrating	NULL
T	NULL
lymphocytes	NULL
.	NULL

Impaired	NULL
response	NULL
to	NULL
mitogen-driven	NULL
stimulation	NULL
despite	NULL
T-cell	NULL
receptor	NULL
expression	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
42	NULL
:	NULL
659-666	NULL
,	NULL
1988	NULL
.	NULL

17	NULL
.	NULL

Yoshino	NULL
,	NULL
I.	NULL
,	NULL
Yuno	NULL
,	NULL
T.	NULL
,	NULL
Murata	NULL
,	NULL
M.	NULL
,	NULL
Ishida	NULL
,	NULL
T.	NULL
,	NULL
Sugimachi	NULL
,	NULL
K.	NULL
,	NULL
Kimura	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Nomoto	NULL
,	NULL
K.	NULL
Tumor-reactive	NULL
T-cells	NULL
accumulate	NULL
in	NULL
lung	NULL
cancer	NULL
tissues	NULL
but	NULL
fail	NULL
to	NULL
respond	NULL
due	NULL
to	NULL
tumor	NULL
cell-derived	NULL
factor	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
52	NULL
:	NULL
775-781	NULL
,	NULL
1992	NULL
.	NULL

18	NULL
.	NULL

Alexander	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Kudoh	NULL
,	NULL
S.	NULL
,	NULL
Melsop	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Hamilton	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
Edinger	NULL
,	NULL
M.	NULL
G.	NULL
,	NULL
Tubbs	NULL
,	NULL
R.	NULL
R.	NULL
,	NULL
Sica	NULL
,	NULL
D.	NULL
,	NULL
Tuason	NULL
,	NULL
L.	NULL
,	NULL
Klein	NULL
,	NULL
E.	NULL
,	NULL
Bukowski	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
and	NULL
Finke	NULL
,	NULL
J.	NULL
H.	NULL
T-cell	NULL
infiltrating	NULL
renal	NULL
cell	NULL
carcinoma	NULL
display	NULL
a	NULL
poor	NULL
proliferative	NULL
response	NULL
even	NULL
though	NULL
they	NULL
can	NULL
produce	NULL
interleukin	NULL
2	NULL
and	NULL
express	NULL
interleukin	NULL
2	NULL
receptors	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
53	NULL
:	NULL
1380-1387	NULL
,	NULL
1993	NULL
.	NULL

19	NULL
.	NULL

Loeffler	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
Smyth	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Longo	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
Kopp	NULL
,	NULL
W.	NULL
C.	NULL
,	NULL
Harvey	NULL
,	NULL
L.	NULL
K.	NULL
,	NULL
Tribble	NULL
,	NULL
H.	NULL
R.	NULL
,	NULL
Tase	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
Urba	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
Leonard	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
Young	NULL
,	NULL
H.	NULL
A.	NULL
,	NULL
and	NULL
Ochoa	NULL
,	NULL
A.	NULL
C.	NULL
Immunoregulation	NULL
in	NULL
cancer-bearing	NULL
hosts	NULL
:	NULL
down-regulation	NULL
of	NULL
gene	NULL
expression	NULL
and	NULL
cytotoxic	NULL
function	NULL
in	NULL
CD8*	NULL
T-cells	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
149	NULL
:	NULL
949-956	NULL
,	NULL
1992	NULL
.	NULL

20	NULL
.	NULL

Mizoguchi	NULL
,	NULL
H.	NULL
,	NULL
O'Shea	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
Longo	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
Loeffler	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
McVicar	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
and	NULL
Ochoa	NULL
,	NULL
A.	NULL
C.	NULL
Alterations	NULL
in	NULL
signal	NULL
transduction	NULL
molecules	NULL
in	NULL
T	NULL
lymphocytes	NULL
from	NULL
tumor-bearing	NULL
mice	NULL
.	NULL

Science	NULL
(	NULL
Washington	NULL
DC	NULL
)	NULL
,	NULL
258	NULL
:	NULL
1795-1798	NULL
,	NULL
1992	NULL
.	NULL

21	NULL
.	NULL

Finke	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
Zea	NULL
,	NULL
A.	NULL
H.	NULL
,	NULL
Stanley	NULL
,	NULL
J.	NULL
,	NULL
Longo	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
Mizoguchi	NULL
,	NULL
H.	NULL
,	NULL
Tubbs	NULL
,	NULL
R.	NULL
R.	NULL
,	NULL
*	NULL
__	NULL
Wiltrout	NULL
,	NULL
R.	NULL
H.	NULL
,	NULL
O'Shea	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
Kudoh	NULL
,	NULL
S.	NULL
,	NULL
Klein	NULL
,	NULL
E.	NULL
,	NULL
Bukowski	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
and	NULL
Ochos	NULL
,	NULL
A.	NULL
C.	NULL
Loss	NULL
of	NULL
T-cell	NULL
receptor	NULL
£	NULL
chain	NULL
and	NULL
pS6'*	NULL
in	NULL
T-cell	NULL
infiltrating	NULL
human	NULL
renal	NULL
cell	NULL
carcinoma	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
53	NULL
:	NULL
5613-5616	NULL
,	NULL
1993	NULL
.	NULL

22	NULL
.	NULL

Nakagomi	NULL
,	NULL
H.	NULL
,	NULL
Petersson	NULL
,	NULL
M.	NULL
,	NULL
Magnusson	NULL
,	NULL
L.	NULL
,	NULL
Jublin	NULL
,	NULL
C.	NULL
,	NULL
Matsuda	NULL
,	NULL
M.	NULL
,	NULL
Melistedt	NULL
,	NULL
H.	NULL
,	NULL
Taupin	NULL
,	NULL
J-L.	NULL
,	NULL
Vivier	NULL
,	NULL
E.	NULL
,	NULL
Anderson	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Kiessling	NULL
,	NULL
R.	NULL
Decreased	NULL
expression	NULL
of	NULL
the	NULL
signal-transducing	NULL
{	NULL
chains	NULL
in	NULL
tumor-infiltrating	NULL
T-cells	NULL
and	NULL
NK	NULL
cells	NULL
of	NULL
patients	NULL
with	NULL
colorectal	NULL
carcinoma	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
53	NULL
:	NULL
5610-5612	NULL
,	NULL
1993	NULL
.	NULL

23	NULL
.	NULL

Altman	NULL
,	NULL
A.	NULL
,	NULL
Coggeshall	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
and	NULL
Mustelin	NULL
,	NULL
T.	NULL
Molecular	NULL
events	NULL
mediating	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Adv	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
48	NULL
:	NULL
227-230	NULL
,	NULL
1990	NULL
.	NULL

24	NULL
.	NULL

Ullman	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
Northrop	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Verweij	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
Transmission	NULL
of	NULL
signals	NULL
from	NULL
the	NULL
T	NULL
lymphocyte	NULL
antigen	NULL
receptor	NULL
to	NULL
the	NULL
genes	NULL
responsible	NULL
for	NULL
cell	NULL
proliferation	NULL
and	NULL
immune	NULL
function	NULL
:	NULL
the	NULL
missing	NULL
link	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
8	NULL
:	NULL
421-452	NULL
,	NULL
1990	NULL
.	NULL

25	NULL
.	NULL

Sen	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
Multiple	NULL
nuclear	NULL
factors	NULL
interact	NULL
with	NULL
the	NULL
immunoglobulin	NULL
enhancer	NULL
sequences	NULL
.	NULL

Cell	NULL
,	NULL
46	NULL
:	NULL
705-716	NULL
,	NULL
1986	NULL
.	NULL

26	NULL
.	NULL

Bacuerle	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

The	NULL
inducible	NULL
transcription	NULL
activator	NULL
NF-	NULL
«	NULL
B	NULL
:	NULL
regulation	NULL
by	NULL
distinct	NULL
protein	NULL
subunits	NULL
.	NULL

Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
,	NULL
1072	NULL
;	NULL
63-80	NULL
,	NULL
1991	NULL
.	NULL

27	NULL
.	NULL

Lowenthal	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
Ballard	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
Bohlein	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Greene	NULL
,	NULL
W.	NULL
C.	NULL
Tumor	NULL
necrosis	NULL
factor	NULL
a	NULL
induces	NULL
proteins	NULL
that	NULL
bind	NULL
specifically	NULL
to	NULL
«	NULL
B-like	NULL
enhancer	NULL
elements	NULL
and	NULL
regulate	NULL
interleukin	NULL
2	NULL
receptor	NULL
a-chain	NULL
gene	NULL
expression	NULL
in	NULL
primary	NULL
human	NULL
T-lympho-cytes	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
86	NULL
:	NULL
2331-2335	NULL
,	NULL
1989	NULL
.	NULL

28	NULL
.	NULL

Molitor	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Walker	NULL
,	NULL
W.	NULL
H.	NULL
,	NULL
Doerre	NULL
,	NULL
D.	NULL
,	NULL
Ballard	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
and	NULL
Greene	NULL
,	NULL
W.	NULL
C.	NULL
NF-	NULL
«	NULL
B	NULL
:	NULL
a	NULL
family	NULL
of	NULL
inducible	NULL
and	NULL
differentially	NULL
expressed	NULL
enhancer-binding	NULL
proteins	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
87	NULL
:	NULL
10028-10032	NULL
,	NULL
1990	NULL
.	NULL

29	NULL
.	NULL

Ballard	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
Walker	NULL
,	NULL
W.	NULL
H.	NULL
,	NULL
Doerre	NULL
,	NULL
S.	NULL
,	NULL
Sista	NULL
,	NULL
P.	NULL
,	NULL
Molitor	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Dixon	NULL
,	NULL
E.	NULL
P.	NULL
,	NULL
Peffer	NULL
,	NULL
N.	NULL
J.	NULL
,	NULL
Hannick	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Greene	NULL
,	NULL
W.	NULL
C.	NULL
The	NULL
v-re	NULL
!	NULL

oncogene	NULL
encodes	NULL
a	NULL
«	NULL
B	NULL
enhancer	NULL
binding	NULL
protein	NULL
that	NULL
inhibits	NULL
NF-	NULL
«	NULL
B	NULL
function	NULL
.	NULL

Cell	NULL
,	NULL
63	NULL
:	NULL
803-814	NULL
,	NULL
1990	NULL
.	NULL

30	NULL
.	NULL

Kieran	NULL
,	NULL
M.	NULL
,	NULL
Blank	NULL
,	NULL
V.	NULL
,	NULL
Logeat	NULL
,	NULL
F.	NULL
,	NULL
Vandekerckhove	NULL
,	NULL
J.	NULL
,	NULL
Lottspeich	NULL
,	NULL
F.	NULL
,	NULL
Le	NULL
Bail	NULL
,	NULL
O.	NULL
,	NULL
Urban	NULL
,	NULL
M.	NULL
B.	NULL
,	NULL
Kourilsky	NULL
,	NULL
P.	NULL
,	NULL
Bacuerle	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
Israel	NULL
,	NULL
A	NULL
.	NULL

The	NULL
DNA	NULL
binding	NULL
subunit	NULL
of	NULL
NF-KB	NULL
is	NULL
identical	NULL
to	NULL
factor	NULL
KBF-I	NULL
and	NULL
homologous	NULL
to	NULL
the	NULL
ref	NULL
oncogene	NULL
product	NULL
.	NULL

Cell	NULL
,	NULL
62	NULL
:	NULL
1007-1018	NULL
,	NULL
1990	NULL
.	NULL

31	NULL
.	NULL

Ghosh	NULL
,	NULL
S.	NULL
,	NULL
Gifford	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
,	NULL
Riviere	NULL
,	NULL
L.	NULL
R.	NULL
,	NULL
Tempst	NULL
,	NULL
P.	NULL
,	NULL
Nolan	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
Cloning	NULL
of	NULL
the	NULL
p50	NULL
DNA	NULL
binding	NULL
subunit	NULL
of	NULL
NF-xB	NULL
:	NULL
homology	NULL
to	NULL
rel	NULL
and	NULL
dorsal	NULL
.	NULL

Cell	NULL
,	NULL
62	NULL
:	NULL
1019-1029	NULL
,	NULL
1990	NULL
.	NULL

32	NULL
.	NULL

Nolan	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
Ghosh	NULL
,	NULL
S.	NULL
,	NULL
Liou	NULL
,	NULL
H.-C.	NULL
,	NULL
Tempst	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
DNA	NULL
binding	NULL
and	NULL
IB	NULL
inhibition	NULL
of	NULL
the	NULL
cloned	NULL
p65	NULL
subunit	NULL
of	NULL
NF-KB	NULL
,	NULL
a	NULL
rel-related	NULL
polypeptide	NULL
.	NULL

Cell	NULL
,	NULL
64	NULL
:	NULL
961-969	NULL
,	NULL
1991	NULL
.	NULL

33	NULL
.	NULL

Ruben	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Dillon	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Schreek	NULL
,	NULL
R.	NULL
,	NULL
Henkel	NULL
,	NULL
T.	NULL
,	NULL
Cohen	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Maher	NULL
,	NULL
M.	NULL
,	NULL
Bacuerie	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
Rosen	NULL
,	NULL
C.	NULL
A	NULL
.	NULL

Isolation	NULL
of	NULL
a	NULL
rel-related	NULL
human	NULL
cDNA	NULL
that	NULL
potentially	NULL
encodes	NULL
the	NULL
65-kD	NULL
subunit	NULL
of	NULL
NF-xB	NULL
.	NULL

Science	NULL
(	NULL
Washington	NULL
DC	NULL
)	NULL
257	NULL
:	NULL
1490-1493	NULL
,	NULL
1991	NULL
.	NULL

34	NULL
.	NULL

Nolan	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
The	NULL
inhibitory	NULL
ankyrin	NULL
and	NULL
activation	NULL
Rel	NULL
proteins	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Genet	NULL
.	NULL

Dev	NULL
.	NULL

,	NULL
2	NULL
:	NULL
211-220	NULL
,	NULL
1992	NULL
.	NULL

35	NULL
.	NULL

Arima	NULL
,	NULL
N.	NULL
,	NULL
Kuziel	NULL
,	NULL
W.	NULL
A.	NULL
,	NULL
Gardina	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
and	NULL
Green	NULL
,	NULL
W.	NULL
C.	NULL
IL-2-induced	NULL
signal	NULL
transduction	NULL
involves	NULL
the	NULL
activation	NULL
of	NULL
nuclear	NULL
NF-KB	NULL
expression	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
149	NULL
;	NULL
83-91	NULL
,	NULL
1992	NULL
.	NULL

36	NULL
.	NULL

Osborn	NULL
,	NULL
L.	NULL
,	NULL
Kunkel	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Nabel	NULL
,	NULL
G.	NULL
J.	NULL
Tumor	NULL
necrosis	NULL
factor	NULL
a	NULL
and	NULL
interleukin	NULL
1	NULL
stimulate	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
enhancer	NULL
by	NULL
activation	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
xB	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
86	NULL
:	NULL
2336-2340	NULL
,	NULL
1989	NULL
.	NULL

37	NULL
.	NULL

Narumi	NULL
,	NULL
S.	NULL
,	NULL
Tebo	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Finke	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
Hamilton	NULL
,	NULL
T.	NULL
A.	NULL
IFNy	NULL
and	NULL
IL2	NULL
cooperatively	NULL
activate	NULL
NFKB	NULL
in	NULL
murine	NULL
peritoneal	NULL
macrophages	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
149	NULL
;	NULL
529-534	NULL
,	NULL
1992	NULL
.	NULL

38	NULL
.	NULL

Granelli-Piperno	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Nolon	NULL
,	NULL
P.	NULL
Nuclear	NULL
transcription	NULL
factors	NULL
that	NULL
bind	NULL
to	NULL
elements	NULL
of	NULL
the	NULL
IL2	NULL
promoter	NULL
:	NULL
induction	NULL
requirements	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
147	NULL
:	NULL
2734-2739	NULL
,	NULL
1991	NULL
.	NULL

39	NULL
.	NULL

Costello	NULL
,	NULL
R.	NULL
,	NULL
Liprey	NULL
,	NULL
C.	NULL
,	NULL
Algarte	NULL
,	NULL
M.	NULL
,	NULL
Cerdon	NULL
,	NULL
C.	NULL
,	NULL
Bacuerle	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
Olive	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Imbert	NULL
,	NULL
J.	NULL
Activation	NULL
of	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
through	NULL
CD2	NULL
plus	NULL
CD28	NULL
adhension	NULL
molecules	NULL
induces	NULL
long-term	NULL
nuclear	NULL
expression	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Cell	NULL
Growth	NULL
&	NULL
Differ	NULL
.	NULL

,	NULL
4	NULL
:	NULL
329-339	NULL
,	NULL
1993	NULL
.	NULL

40	NULL
.	NULL

Kang	NULL
,	NULL
S-M.	NULL
,	NULL
Tran	NULL
,	NULL
A-C.	NULL
,	NULL
Grilli	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Leonardo	NULL
,	NULL
M.	NULL
J.	NULL
NF-xB	NULL
subunit	NULL
regulation	NULL
in	NULL
5428	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1994	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

ALTERED	NULL
«	NULL
B	NULL
BINDING	NULL
ACTIVITY	NULL
IN	NULL
T	NULL
CELLS	NULL
nontransformed	NULL
CD4*	NULL
T	NULL
lymphocytes	NULL
.	NULL

Science	NULL
(	NULL
Washington	NULL
DC	NULL
)	NULL
256	NULL
:	NULL
1452-1456	NULL
,	NULL
1992	NULL
.	NULL

Brownell	NULL
,	NULL
E.	NULL
,	NULL
Ruscretti	NULL
,	NULL
F.	NULL
W.	NULL
,	NULL
Smith	NULL
,	NULL
R.	NULL
G.	NULL
,	NULL
and	NULL
Rice	NULL
,	NULL
N.	NULL
R.	NULL
Detection	NULL
of	NULL
rel-related	NULL
RNA	NULL
and	NULL
protein	NULL
in	NULL
human	NULL
lymphoid	NULL
cells	NULL
.	NULL

Oncogene	NULL
,	NULL
3	NULL
:	NULL
93-98	NULL
,	NULL
1989	NULL
.	NULL

Ghosh	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
Activation	NULL
in	NULL
vitro	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
phosphorylation	NULL
of	NULL
its	NULL
inhibitor	NULL
IB	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
344	NULL
:	NULL
678-682	NULL
,	NULL
1990	NULL
.	NULL

Weiss	NULL
,	NULL
A.	NULL
,	NULL
Koretzky	NULL
,	NULL
G.	NULL
,	NULL
Schatzman	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Kadlecek	NULL
,	NULL
T.	NULL
Functional	NULL
activation	NULL
of	NULL
the	NULL
T-cell	NULL
antigen	NULL
receptor	NULL
induces	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
phospholipase	NULL
C-y	NULL
1	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
88	NULL
:	NULL
5484-5488	NULL
,	NULL
1991.	NULL
.	NULL

Gosh	NULL
,	NULL
P.	NULL
,	NULL
Sica	NULL
,	NULL
A.	NULL
,	NULL
Young	NULL
,	NULL
H.	NULL
,	NULL
Jianping	NULL
,	NULL
Ye	NULL
.	NULL

,	NULL
Franco	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Wiltrout	NULL
,	NULL
R.	NULL
H.	NULL
,	NULL
Longo	NULL
,	NULL
5429	NULL
45	NULL
.	NULL

D.	NULL
L.	NULL
,	NULL
Rice	NULL
,	NULL
N.	NULL
R.	NULL
,	NULL
and	NULL
Kromschlies	NULL
,	NULL
K.	NULL
L.	NULL
Alterations	NULL
in	NULL
NFxB/rel	NULL
family	NULL
proteins	NULL
in	NULL
splenic	NULL
T-cells	NULL
from	NULL
tumor-bearing	NULL
mice	NULL
and	NULL
reversal	NULL
following	NULL
therapy	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
54	NULL
:	NULL
2969-2972	NULL
,	NULL
1994	NULL
.	NULL

Gastel	NULL
,	NULL
G.	NULL
,	NULL
Liu	NULL
,	NULL
F.	NULL
,	NULL
Findstad	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
Nanus	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
and	NULL
Bander	NULL
,	NULL
N.	NULL
H.	NULL
Local	NULL
expression	NULL
of	NULL
immune	NULL
response	NULL
genes	NULL
in	NULL
human	NULL
renal	NULL
cancer	NULL
.	NULL

Proc	NULL
.	NULL

Am	NULL
.	NULL

Assoc	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
33	NULL
:	NULL
353	NULL
,	NULL
1992.	NULL
.	NULL

Ikemoto	NULL
,	NULL
S.	NULL
,	NULL
Wada	NULL
,	NULL
S.	NULL
,	NULL
Kamizuru	NULL
,	NULL
M.	NULL
,	NULL
Hayahara	NULL
,	NULL
N.	NULL
,	NULL
Kishimoto	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Mackawa	NULL
,	NULL
M.	NULL
Clinical	NULL
studies	NULL
on	NULL
cell-mediated	NULL
immunity	NULL
in	NULL
patients	NULL
with	NULL
renal	NULL
cell	NULL
carcinoma	NULL
interleukin-2	NULL
and	NULL
interferon-y	NULL
production	NULL
of	NULL
lymphocytes	NULL
.	NULL

Cancer	NULL
Immunol	NULL
.	NULL

Immu-nother	NULL
.	NULL

,	NULL
34	NULL
:	NULL
289-293	NULL
,	NULL
1992	NULL
.	NULL

Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1994	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

AAGR	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
Cancer	NULL
Research	NULL
The	NULL
Journal	NULL
of	NULL
Cancer	NULL
Research	NULL
(	NULL
1916-1930	NULL
)	NULL
|	NULL
The	NULL
American	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
1931-1940	NULL
)	NULL
T	NULL
Cells	NULL
from	NULL
Renal	NULL
Cell	NULL
Carcinoma	NULL
Patients	NULL
Exhibit	NULL
an	NULL
Abnormal	NULL
Pattern	NULL
of	NULL
<	NULL
B-specific	NULL
DNA-binding	NULL
Activity	NULL
:	NULL
A	NULL
Preliminary	NULL
Report	NULL
Xiaoli	NULL
Li	NULL
,	NULL
Jun	NULL
Liu	NULL
,	NULL
Jeong-Kyu	NULL
Park	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Cancer	NULL
Res	NULL
1994	NULL
;	NULL
54:5424-5429	NULL
.	NULL

Updated	NULL
version	NULL
_	NULL
Access	NULL
the	NULL
most	NULL
recent	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/54/20/5424	NULL
E-mail	NULL
alerts	NULL
_	NULL
Sign	NULL
up	NULL
to	NULL
receive	NULL
free	NULL
email-alerts	NULL
related	NULL
to	NULL
this	NULL
article	NULL
or	NULL
journal	NULL
.	NULL

Reprints	NULL
and	NULL
_	NULL
To	NULL
order	NULL
reprints	NULL
of	NULL
this	NULL
article	NULL
or	NULL
to	NULL
subscribe	NULL
to	NULL
the	NULL
journal	NULL
,	NULL
contact	NULL
the	NULL
AACR	NULL
Publications	NULL
Subscriptions	NULL
_	NULL
Department	NULL
at	NULL
pubs	NULL
@	NULL
aacr.org	NULL
.	NULL

Permissions	NULL
_	NULL
To	NULL
request	NULL
permission	NULL
to	NULL
re-use	NULL
all	NULL
or	NULL
part	NULL
of	NULL
this	NULL
article	NULL
,	NULL
use	NULL
this	NULL
link	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/54/20/5424	NULL
.	NULL

Click	NULL
on	NULL
``	NULL
Request	NULL
Permissions	NULL
``	NULL
which	NULL
will	NULL
take	NULL
you	NULL
to	NULL
the	NULL
Copyright	NULL
Clearance	NULL
Center	NULL
's	NULL
(	NULL
CCC	NULL
)	NULL
Rightslink	NULL
site	NULL
.	NULL

Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1994	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

